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ABSTRACT 
Delivery of therapeutic molecules to the eye has been a complicated task owing to its anatomical 
and physiological barriers. This dissertation delineates several formulation strategies to 
circumvent dynamic and static constraints hampering the ocular drug delivery.   
 Advanced vesicular systems, bilosomes and transfersomes, were prepared to improve the 
ocular pharmacotherapy of natamycin (NT). NT bilosomes and transfersomes were further loaded 
into in situ gel systems which transformed immediately to hydrogel, in the simulated tear fluid, 
with good viscoelastic and mucoadhesive properties. In vitro corneal transport studies confirmed 
the superior permeability characteristics of NT from the optimized bilosome and transfersome in 
situ gel formulations, over control marketed (5 % w/v NT) suspension. In the ocular distribution 
studies, considerably higher mean dose normalized drug levels in the ocular tissues from bilosome 
and transfersome in situ gel formulations for 6h, compared to that from the control suspension, 
demonstrated the effectiveness of ion-sensitive in situ hydrogels of bilosomes and transfersomes 
as potential carrier systems for improved and prolonged topical ocular drug delivery.  
 The magnitude of P-glycoprotein (P-gp) and multidrug resistance protein (MRP1) were 
investigated by comparative ocular distribution studies in the P-gp and MRP1 gene knock out (KO) 
and wild type (WT) rats. The blood ocular penetration of paclitaxel (PTX), a P-gp substrate and, 
methotrexate (MTX), an MRP 1 substrate, were significantly higher in the KO rats compared to 
WT rats. These results suggested that the penetration of anticancer substrate drugs across the BOB 
is restricted by efflux transporter proteins. Further, the concurrent intravenous administration of 
specific P-gp and MRP 1 inhibitors, along with PTX or MTX, in the WT rats resulted in improved 
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blood ocular penetration of substrate anticancer drugs by effective inhibition of efflux protein 
activity in the BOB. The electroretinography (ERG) studies demonstrated that the inhibitor and 
substrate interactions did not induce any toxic effects on retina functions. However, at higher 
concentration of PTX and MTX showed toxic effects on the retina functions.  
 Feasibility of coadministration of topical ocular inserts of P-gp inhibitors and 
intravenous anticancer substrate drug, PTX, was investigated in rats to examine the potential of 
this strategy to improve blood ocular penetration of PTX. Ocular films of P-gp inhibitors were 
fabricated by melt cast method and the transocular membrane permeability of the P-gp inhibitors, 
elacridar (EQ) and tariquidar (TQ), was investigated in the isolated rabbit cornea. Both EQ and 
TQ showed transcorneal permeability but no penetration through Sclera-choroidal retinal 
pigmented epithelium (RPE) tissue. The ocular distribution studies in rats showed improved blood 
ocular penetration of PTX in the rats co-administered with EQ and TQ. These results demonstrated 
that the topically administered P-gp inhibitor effectively inhibits the P-gp activity and thereby 
improves ocular chemotherapy. ERG and Ultrastructure analyses of RPE confirmed that the PTX-
EQ/TQ interactions were compatible with retina.  
TA protransfersome gel formulations were successfully prepared with at least two-fold higher drug 
load, compared to the marketed topical dosage form, which allows higher, localized, concentration 
gradients. Microscopic studies confirmed complete drug dissolution in the lipid phase and rapid 
formation of transfersomes on hydration. Significantly higher trans-eyelid TA permeation with the 
protransfersome gel formulation – demonstrated their potential in enhancing drug delivery to the 
ocular surface and deeper tissues via the eyelid. Experiments in dead rabbits confirmed that TA 
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efficiently penetrated into the eyelid and formed a depot leading to increasing concentration-time 
profiles in all ocular tissues tested. The overall results suggest that trans-eyelid protransferosome 
gel formulations can provide a platform for the sustained delivery of therapeutic agents to both the 
surface of the eye as well as the anterior and posterior segment ocular tissues. 
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CHAPTER 1 
INTRODUCTION  
1.1. Introduction 
        Eye, the most important and sensitive organ, regulates the visual sensory activities in 
the humans. The architecture of the eye is extremely complex with the intraocular tissues aligned 
in two segments, namely, the anterior segment and the posterior segment (Fig 1.1). Conjunctiva, 
cornea, aqueous humor (AH), iris, ciliary body, trabecular meshwork, schlemm’s canal, pupil, and 
lens are situated in the anterior segment. Most of these tissues control the aqueous humor dynamics 
which maintains the intraocular pressure. Sclera, choroid, retina, vitreous humor (VH) and optic 
nerve constitutes posterior segment. The rods and cones in the retina play a critical role in 
Figure 1.1: Anatomy of the human eye 
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processing the visual information in the central nervous system. Any damage, either by 
disease or injury, to the eye may lead to the temporary or permanent vision problems 
1.1.1. Ocular Protective Barriers 
The anatomical and physiological barriers that safeguard the eyes from toxins or xenobiotics from 
external environment or systemic circulation are presented in table 1.1.  
 
Physiological Anatomical 
1. Lacrimal discharge 
2. Tear turnover 
3. Tear film 
4. Reflux blinking 
5. Naso-lacrimal drainage  
6. Pre-corneal metabolism 
7. Aqueous humor outflow 
6. Conjunctiva ultrastructure 
7. Cornea ultrastructure 
8. Sclera  
9. Choroid 
10. Bruch’s membrane 
11. Blood ocular barriers (BOB) 
o Blood aqueous barriers  
o Blood retinal barriers 
 
1.1.1.1. Physiological barriers 
The physiological barriers lower precorneal residence time of the toxins or xenobiotics, from the 
external environment (topical), through increased lacrimation, dilution by tear, reflux blinking and 
nasolacrimal drainage. Moreover, the precorneal metabolism results in precorneal loss and, thus, 
prevents the entry of toxic materials into the ocular compartments (1, 2). 
1.1.1.2. Anatomical Barriers  
Anatomical barriers restrict the penetration of toxins from the external environment and protect 
the deeper ocular tissues. The conjunctiva vasculature, unique structural features of the cornea, 
Table 1.1: Physiological and anatomical protective barriers in the eye.  
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with the hydrophilic stroma sandwiched between the hydrophobic epithelium and the endothelium, 
and sclera limits the permeability of the xenobiotics (2). The presence of complex blood ocular 
barriers (BOB) comprising; blood-aqueous barrier (BAB), and the blood-retinal barrier (BRB), 
with tight-junction proteins and the efflux proteins (P-gp/MRP 1), protect the anterior and posterior 
segment ocular tissues by preventing the paracellular and/or transcellular transportation of 
endobiotics and xenobiotics from the systemic circulation (3, 4). 
1.1.2. Eye Ailments  
In 2011, as per the World Health Organization (WHO) report, approximately 285 million global 
population is suffering from eye ailments. Additionally, National Eye Institute (NEI) reported 
more than 30 million individuals in the United States suffering from ocular diseases (5, 6). Age-
related macular degeneration (AMD), diabetic retinopathy (DR), uveitis, retinoblastoma, dry eyes, 
conjunctivitis, keratomycosis, blepharitis, postoperative endophthalmitis, corneal ulcers, bacterial 
keratitis, mycotic keratitis, choroidal neovascularization (CNV) and retinitis pigmentosa were the 
most commonly encountered eye diseases worldwide (7-10). These diseases involve infection, 
inflammation and/or oxidative stress (alone or in combination) of anterior and posterior segment 
ocular tissues. It is predicted that these numbers would be doubled by 2050 (2,11,12). Alone in 
USA, approximately $40 billion/year expenditure is incurred in the treatment of ocular disorders, 
and, more than a half of the treatment regimen includes anti-infective and steroidal anti-
inflammatory agents (11,12).  
 Currently, conventional, topical ophthalmic formulations are utilized for the treatment of 
external eye surface and anterior ocular tissue infections/inflammation (1,2). A host of 
physiological and anatomical protective barriers shorten the precorneal residence and restricts the 
ocular penetration of therapeutic agents from these topical formulations (1,2,13). Thus, frequent 
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administration (3 - 6 times/day) is often needed to maintain therapeutic drug levels (1,2,13), which 
leads to noncompliance issues. Moreover, the topical route of administration has not been effective 
in the treatment of conditions affecting the back-of-the eye, for which intravitreal 
injections/systemic administration are the best options (13,14). Poor patient compliance and 
injection associated risks, however, are major challenges for intravitreal injections (13,15). While, 
drugs from systemic circulation need to overcome the blood ocular barriers for which higher dose 
administration is required, that could result in systemic toxicity (14). Hence, there is an urgent 
need for robust noninvasive drug delivery platforms that can improve and prolong therapeutic drug 
levels in the anterior and posterior ocular segments.  
1.2. Specific Objectives: 
      The major objective of this project is to develop novel topical ophthalmic formulations 
of Natamycin (NT), an anti-fungal agent, Triamcinalone acetonide (TA), a steroidal anti-
inflammatory agent, and P-gp/Mrp 1 inhibitors. NT and TA are used in the treatment of ocular 
fungal infections and inflammations. P-gp/Mrp 1 inhibitors are utilized in the inhibition of the P-
gp/Mrp1 activity in the BOB to improve blood ocular penetration of chemotherapeutics. The 
selected molecules were formulated and tested for in vitro and in vivo performance to demonstrate 
the potential of advanced vesicular in situ hydrogels and melt-cast films for improved and 
prolonged ocular pharmacotherapy. 
1.3. Specific Aims 
1. Development and evaluation of the ion sensitive in situ hydrogels of NT loaded vesicular 
systems for improved and prolonged ocular delivery.   
2. Screening, development and evaluation of P-gp/Mrp1 inhibitor loaded topical melt cast films 
for improved blood ocular penetration of substrate chemotherapeutic drugs.  
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2.1. Evaluation of the impact of efflux proteins activity and inhibition in the blood ocular 
barriers for improved ocular delivery of chemotherapeutic agents. 
2.2. Development and evaluation of specific inhibitor loaded topical ophthalmic melt-cast 
films for the inhibition of P-gp/Mrp1 activity in the blood ocular barriers to improve 
blood ocular penetration of substrate chemotherapeutic drugs. 
3 Development, quality control, and in vivo evaluation of protransfersomes gel formulation for 
improved and prolonged ocular drug delivery through eyelid application. 
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CHAPTER 2 
ION SENSITIVE IN SITU HYDROGELS OF ADVANCED NATAMYCIN LOADED 
VESICULAR SYSTEMS FOR IMPROVED AND PROLONGED OCULAR 
PHARMACOTHERAPY 
2.1. Introduction 
Despite advancement in the field of pharmaceutical technology, effective topical ocular drug 
delivery is still a complicated task for formulation scientists due to the complex anatomical, 
physiological and formulation constraints (16-18). Beside various protective ocular barriers, short 
pre-corneal residence and poor corneal permeability are the key factors contributing to low ocular 
bioavailability (< 5%) of the therapeutics instilled as conventional ophthalmic dosage forms (14, 
16-19). The increased lacrimation, reflux blinking and nasolacrimal drainage accounts for the rapid 
elimination of the drugs from the cul-de-sac (17,18). Various formulations like ocular ointments, 
hydrogels, polymeric or ion-exchange resin based topical ocular inserts and in situ gel systems 
have been reported to improve the residence of the drugs in the pre-corneal space (20-23). In situ 
hydrogels have better patient compliance unlike ocular ointments and inserts which causes blurred 
vision and grittiness influenced distressed blinking (22,24,25). The in situ gel systems are solutions 
which undergo phase transition to form viscoelastic hydrogel in the ocular milieu in response to 
the temperature, pH, electrolytes or ions and photo radiation (22,24,25). Due to the abundance of 
electrolytes in tear fluid, the ion or electrolyte sensitive in situ hydrogel formation is triggered at 
lower polymer concentrations with respect to that induced by other stimuli (26,27). 
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 The distinct anatomical features of the cornea, with hydrophilic stroma sandwiched 
between lipophilic epithelium and endothelium, restricts the penetration of hydrophilic and 
lipophilic drugs into the deeper ocular tissues [16-19, 28]. Numerous lipid/polymeric nano-
formulations such as solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), 
polymeric nanoparticles (PN), micelles and phospholipid or non-ionic surfactant based vesicles 
have shown success in enhancing the transcorneal drug permeability (29-34). The combination of 
in situ gel systems and nanocarriers offers improved tear/corneal surface contact time and corneal 
permeability of the drugs (35). Several pH and/or temperature triggered in situ gel forming systems 
of SLN, polymeric nanoparticles, nanoemulsions, liposomes and niosomes have been successfully 
investigated as suitable ocular drug delivery platforms (35-39).  
 In recent years, advanced vesicular systems, bilosomes and transfersomes, have emerged 
as potential carriers for improved oral, nasal and/or transdermal delivery of small and large 
molecules due to their ultra-deformable and flexible properties (40-42).  The inclusion of the 
amphiphilic bile salt (bilosomes) or hydrophilic edge activator (transfersomes) in the vesicle 
bilayer allows bilosomes and transfersomes to penetrate through the intercellular lipid layers of 
intact biological membranes, such as skin, nasal mucosa and intestine (41-44]). Considering these 
advantages, a few studies investigated the suitability of bilosomes and transfersomes for improved 
ex vivo corneal permeability of a lipophilic molecule (42,44). To the best of our knowledge, 
bilosomes and transfersomes ion sensitive in situ hydrogel forming systems have not been 
investigated till date.   
 In this study, we report the fabrication and evaluation of ion sensitive in situ hydrogels of 
natamycin (NT)-loaded bilosomes (NB) and transfersomes (FN) for improved ocular 
pharmacotherapy. NT, a macrolide polyene antifungal agent, is the only commercially available 
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ophthalmic product (Natacyn® (NT 5% w/v suspension)) approved by US-FDA for treating fungal 
keratitis and other fungal infections (45). Due to poor aqueous solubility, limited corneal 
permeability and low precorneal residence time of NT, current therapy requires multiple dosing (a 
drop every 1-2h) for several weeks (4-6 weeks) to attain and/or maintain therapeutic concentrations 
at the desired site (45,46). Hence, there is a need to develop a delivery system, with improved NT 
corneal permeability and prolonged drug levels in the ocular sites, for improved patient 
compliance. A few literature reports described improved NT levels in the tear and prolonged in 
vitro corneal drug permeability from mucoadhesive nanoparticles and niosomes thermosensitive 
in situ gels, respectively [39,47]. However, there are no reports on the ocular disposition of NT or 
any other drug from topically instilled bilosomes and transfersomes in situ gels. 
    Thus, for the first time, the ocular disposition of ion sensitive in situ hydrogel forming system 
of NB and FN are evaluated in the New Zealand male albino rabbits.  
2.2. Materials and Methods 
NT was procured from Cayman Chemical (Ann Arbor, MI, USA). Sodium taurocholate (ST) was 
obtained from Biosynth International, Inc. (Itasca, IL, USA). Phospholipon 90H (PL) was procured 
from Lipoid, LLC (Newark, NJ, USA), Kolliphor TPGS (D-alpha tocopheryl polyethylene glycol 
1000 succinate) (T) was obtained from BASF Corporation (NJ, USA), (Sorbitan monostearate 
(Span 60 (S60)) and MTT reagent (Methylthiazolyldiphenyl-tetrazolium bromide) were received 
from Sigma Aldrich (St. Louis, MO, USA. Cholesterol (CH) was procured from Alfa Aesar (Ward 
Hill, MA, USA). Gelan Gum (G) and Xanthum gum (X) were purchased from MP Biomedicals, 
LLC (Santa Ana, CA, USA). DMEM/F-12 (Dulbecco's Modified Eagle Medium/Nutrient Mixture 
F-12) was procured from Mediatech, Inc. (A Corning Subsidiary Manassas, VA). Glycerin, 
Amicon® Ultracentrifugal filter devices with regenerated cellulose membrane (molecular weight 
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cut off 100 kDa), high performance liquid chromatography (HPLC) - grade solvents, and other 
chemicals (analytical grade) were supplied by Fisher Scientific (Hampton, NH, USA). Whole eyes 
of male albino New Zealand rabbits were obtained from Pel-Freez Biologicals (Rogers, AR). Male 
albino New Zealand rabbits were procured from Harlan Labs (Indianapolis, IN). 
2.2.1. Quantification of natamycin  
The NT content in all the samples was determined with HPLC-UV (ultraviolet) method, as 
reported earlier, with minor modifications (48). In brief, a mobile phase of acetonitrile and 0.02 M 
potassium dihydrogen phosphate (30:70 % v/v) mixture (pH 5.5) was pumped through a 
phenomenex Luna® C18(2) 100 Å column (4.6 mm x 250 mm; 5µ particle size), at a flow rate of 
1.0 mL/min, by Water 600 controller pump in HPLC system. A 20 µL sample was injected by 
Waters 717 plus Autosampler into the mobile phase and the column eluent was monitored at 
λmax (detection wavelength) of 304 nm using Waters 2487 Dual λ Absorbance detector. The 
absorbance peaks were recorded with the help of Agilent 3395 Integrator.  
2.2.2. Preparation of natamycin bilosomes and in situ gel formulations 
 The film hydration technique was employed to prepare the natamycin bilosomes (NB) (37,49). 
Briefly, in 20 mL of organic solvent mixture of chloroform, ethanol and methanol (7:1:2), 
accurately weighed quantities of lipid mixture (210 or 230 µM of S60 and CH taken in 2:1, 1:1 
and 1:2 molar ratios) and drug were dissolved in a round bottom (RB) flask. The RB ﬂask was 
then mounted onto a rotary ﬂash evaporator (Laborota 4000, Heidolph, Germany) operated at 200 
rpm for 30 min at 45 ± 5°C to evaporate the organic solvent, under vacuum, leaving a thin film of 
lipid on the wall of the flask. The lipid film was dried in vacuum oven at 40°C for 2h and then 
hydrated with the deionized water (8-10 mL) containing ST (20 or 40 µM) and glycerin, 
maintained at 60 ± 5°C, to form NB with vigorous shaking. Further, the NB was sonicated with 
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probe sonicator (Vibra-Cell™ Ultrasonic, Sonics and Material INC., CT, USA) for 5 min with 
pulse on for 20 secs and off for 40 secs at 30 % amplitude.  
The NB in situ gel NBG or NBX formulations were obtained by adding 8 mL of NB 2 to 
2 mL of G or X dissolved in deionized water (60 ± 5°C). The formulations were allowed to cool 
to room temperature and stored in screw-capped glass vials until further evaluation. The 
composition of the NB and NBG or NBX formulations are presented in Table 2.1. 
2.2.3. Preparation of natamycin transfersomes and in situ gel formulations 
The NT transfersomes formulations (FN) were prepared by the film hydration technique (42,49). 
Accurately weighed quantities of PL, S60, TPGS and NT were dissolved in 20 mL of organic 
solvent mixture (chloroform, ethanol and methanol (7:1:2)), in a round bottom (RB) flask (Table 
2.2). The RB ﬂask was then mounted onto a rotary ﬂash evaporator (Laborota 4000, Heidolph, 
Germany) operated at 200 rpm for 30 min at 45 ± 5°C to evaporate the organic solvent, under 
vacuum, leaving a thin residual lipid film on the flask wall. The lipid film was dried in vacuum 
oven at 40°C for 2h and then hydrated with the deionized water (8-10 mL) containing glycerin, 
maintained at 60 ± 5°C, to form transfersomes with vigorous shaking. Further, the FN was 
sonicated with probe sonicator (Vibra-Cell™ Ultrasonic, Sonics and Material INC., CT, USA) for 
5 min with pulse on for 20 secs and off for 40 secs at 30 % amplitude.  
The FN in situ gel formulations (FNG) were obtained by adding 8 mL of FN 2 to 2 mL of G 
dissolved in deionized water (60 ± 5°C). The formulations were allowed to cool to room 
temperature and stored in screw-capped glass vials until further evaluation. The composition of 
the FN and FNG formulations are presented in Table 2.2.  
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2.2.4. Particle size, zeta potential and polydispersity index measurement 
The mean particle size (PS) and polydispersity index (PDI) of the NB, NBG, NBX, FN and FNG 
formulations were determined by dynamic light scattering using Zetasizer Nano ZS Zen3600 
(Malvern Instruments, Inc. UK). Samples were suitably diluted with filtered double distilled water 
(0.2 μm nylon filter) and analysis was performed at 25°C and 173° angle of detection using a 
helium-neon laser of 633 nm, in disposable clear cells. Zeta potential (ZP) measurements were also 
carried out at 25°C using the laser Doppler velocimetry function of the same instrument.  
2.2.5. Drug Content and Entrapment Efficiency  
The drug content was determined by extracting the NT from the formulations using methanol and 
190-proof alcohol (70:30 %v/v) then centrifuged (AccuSpin 17R centrifuge, Fisher Scientiﬁc, 
USA) at 13,000 rpm for 20 min. The supernatant was separated, appropriately diluted and 
quantified for the drug content by HPLC.  
The percentage drug entrapment efficiency (% EE) was determined by estimating the free NT 
concentration in the dispersion medium using ultra-filtration technique. In brief, 500 μL of each 
formulation was added to the sample reservoir of the Amicon Ultra-centrifugal filter device 
(Molecular weight cutoff of 100 kilo Daltons) (Fisher Scientiﬁc, USA) and centrifuged at 5,000
rpm for 10 min (AccuSpin 17R centrifuge, Fisher Scientiﬁc, USA). The NT content in the aqueous 
filtrate was evaluated by HPLC. The % EE was calculated from the Eq. (1). The experiment was 
carried out in triplicate.                                                                                                                         
                                                           %EE   	 
 100                               (1) 
Where Wi =total drug content, and Wf =amount of free drug in aqueous phase. 
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2.2.6. In vitro gelation behavior of NB and FN in situ gels 
 The gelling capacity of bilosomes (NBG or NBX) and transfersomes (FNG) in situ gel 
formulations was visually evaluated by determining the gel formation time (GT) and residence 
time (GRT) of intact gel without dissolution or breaking (39,50). Briefly, 50 µL of NBG or NBX 
and FNG formulations was dropped into a separate glass vials with 2 mL of freshly prepared 
simulated tear fluid (STF) and maintained at 34 ℃ in a shaking water bath (Precision™, Fisher 
Scientiﬁc, USA) operated at 100 rpm for 12h. The time taken for the transformation of sol-to-gel 
by NBG or NBX and FNG formulations was recorded as the gel formation time (GT). Each vial 
was visually inspected every hour and the time required for the gel to dissolve or break was 
recorded as the intact gel residence time (GRT).  
2.2.7. Rheological studies  
The viscosity of the NB 2, NBG, NBX, FN 2 and FNG formulations were measured on Brookfield 
cone and plate viscometer (LVDV-II+ Pro Viscometer, Middleboro, USA). Briefly, 500 µL of 
each formulation was placed in the cup plate, and the gap between cone and plate was adjusted. 
The samples in the cup were maintained at 25°C using a circulating water bath. A CP-40 
Cone/Spindle was operated at 0.1, 1 and 10 rpm and the viscosity was recorded from Rheocalc 
software. To determine viscosity of the hydrogels, 500 µL of mixture of bilosomes in situ gel or 
transfersomes in situ gel formulations and STF (50:7) was placed in cup plate and similar 
procedure was repeated to record viscosity (n=3) (37).  
2.2.8. Texture analysis 
The adhesive strength of hydrogels obtained from NBX, NBG and FNG formulations were 
evaluated with TA.XT2i texture analyzer (Texture Technologies Corp. NY. USA) set to the 
compression mode (51). The hydrogels were placed in soft matter holder (TA-275) positioned 
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below the acrylic cylindrical probe (1-in. diameter (TA-3)) which was then lowered into the 
product (1mm distance from the surface) at a test-speed of 0.5 mm/s with 3 g trigger force. An 
acquisition rate of 500 points/sec was selected and the texture analysis was conducted at room 
temperature (n=3).  
2.2.9. Transmission electron microscopy   
 
The morphology of the vesicles in the NB 2, NBG 2, FN 2 and FNG 3 formulations were evaluated 
by transmission electron microscopy (TEM) (JEOL JEM1200EX II electron microscope) as per 
the published protocol with minor modifications (52). Briefly, the formulations were centrifuged 
for 1h at 25,000 rpm and 15°C (SORVALL, WX Ultra Series Centrifuge, USA) to separate the 
bilosomes and transfersomes pellets which were then resuspended in 5ml deionized water and 
recentrifuged (as mentioned earlier). This step is repeated 3 times to wash out any soluble 
impurities. The resuspended bilosomes and transfersomes were centrifuged for 5min at 2000 rpm 
(15°C) (Eppendorf AG centrifuge, Hamburg, Germany), to separate the aggregates/insoluble 
impurities, and the clean vesicular suspensions were then diluted 1:100 with deionized water. 2 μL 
of the diluted suspension was placed on 400 mesh copper grids covered with Formvar film 
(Electron Microscopy Sciences EMS, Hatfield, PA, USA). The grids were allowed to dry overnight 
in a desiccator and then examined by TEM. 
2.2.10. Fourier transform infrared spectroscopy (FTIR)  
The infrared spectra of drug, sodium taurocholate, phospholipon 90H, TPGS, cholesterol, span 60 
NBG 2 and FNG 3 samples were recorded using Cary 660 series FTIR (Agilent Technologies, 
USA) to understand the chemical compatibility between the drug and excipients.  
2.2.11. Stability studies 
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The NB 2, NBG 2, FN 2 and FNG 3 formulations were taken in glass vials, wrapped in aluminum 
foil and stored at 4°C and 25°C for 60 days. Their physical and chemical stability, on storage, were 
evaluated by withdrawing the samples at definite time intervals (0, 30 and 60 days) and analyzing 
the particle size, PDI, zeta potential, % EE and drug content as described earlier.  
2.2.12. In vitro cytotoxicity  
In vitro cytotoxicity of NB 2, NBG 2, FN 2, FN 5 and FNG 3 formulations were evaluated by the 
methyl thiazolyl tetrazolium (MTT) assay. Normal saline and triton x 100 served as negative and 
positive controls for the experiment respectively. The assay was carried out in 96-well plates 
(Costar 3596, Corning Inc., Corning, NY). Briefly, 100 μl of the human corneal limbal epithelial 
(HCLE) cells were plated at a concentration of 15x104 cell/mL, and incubated in an incubator at 
37°C with 5% CO2 for 24h in culture medium (DMEM/F-12 50:50, with 10% calf serum, and 1% 
penicillin/streptomycin). Then, 100 μl of the diluted formulations, negative control (normal 
saline), NB 2, NBG 2, FN 2, FN 5, FNG 3 and positive control (triton X 100)) (i.e., 50 μl 
formulation + 50 μl of DMEM/F-12 50:50 Medium) was added to each well. After 24h incubation, 
the formulations were removed, and the cells were washed twice with the culture medium to 
remove all traces of the formulations. 100 μl of MTT reagent (1 mg/ml in culture medium without 
serum) was added to each well and the plates were incubated at 37°C for 4h. During the incubation, 
the active enzymes (mitochondrial reductase) of the viable cells converted the yellow MTT dye 
into purple formazan crystals. After incubation, the medium was removed and 100 μl DMSO was 
added to each well to dissolve the formazan crystals and the intensity of color was assessed at 570 
nm with µ-Quant universal microplate spectrophotometer (Bio-Tek Instruments, Inc. Winooski, 
VT).  
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2.2.13. In vitro corneal permeation studies  
In vitro transcorneal permeation studies were performed in the corneas separated from rabbit whole 
eyes shipped overnight in Hanks balanced salt solution (over wet ice) from Pel-Freez Biologicals. 
They were used immediately upon receipt. To confirm the secure mounting between the donor and 
receiver chambers of diffusion cell during the study period, corneas were excised with some scleral 
portion. They were placed on Valia-Chien cells (PermeGear, Inc®), maintained at 34°C, with the 
endothelial side facing receiver chamber while the epithelial side facing the donor chamber. 200 
µL of control (Natacyn ®), NB 2, NBG 2, FN 2, FN 5 and FNG 3 formulations were added to the 
individual donor chambers. 50 µL of DPBS was placed in the donor chamber holding 200 µL of 
NBG 2 or FNG 3 formulation to ensure the hydrogel formation. The Natacyn ® suspension was 
diluted to obtain 0.1% w/v NT, equivalent to that in NB 2 and NBG 2 formulations. The receiver 
chamber was filled with 5 mL of DPBS (pH 7.4) with 2.5% w/v of RMβCD medium. At 
predetermined time points, an aliquot of 600  µL was withdrawn from the receiver chamber and 
replenished with equal volume of fresh medium to maintain the constant volume, until 3h. Samples 
were stored at −20°C until further analysis by HPLC.  
2.2.14. Data analysis 
The transcorneal permeation parameters across rabbit cornea such as the cumulative amount of 
drug permeated (Mn), steady state flux (J) and the apparent permeability coefﬁcient (Papp) were 
calculated as per the earlier reports (53). The cumulative amount of NT permeated across the 
cornea was determined using the equation Eq. (2). 
 	 	∑                                     (2) 
Where: n indicates sampling time point (n = 1, 2, 3….8 corresponding to 15, 30, 45….180 min 
respectively); Vr and VS represents the volume of the medium in the receiver chamber (mL) and 
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the volume of the sample collected at the nth time point (mL); and Cr(n) specifies the concentration 
of the drug in the receiver chamber medium at nth time point (µg/mL). 
 The rate of NT transported through the rabbit cornea was computed from the slope of the 
cumulative amount of NT permeated vs. time (t) plot. The steady-state flux (SSF) (J) of natamycin 
was calculated according to the following equation (Eq. (3)) (30): 
                                                   / "/#                                          (3) 
Where M and A designates the cumulative amount of drug transported and the surface area of the 
cornea utilized in the experiment (0.636 cm2). 
The transcorneal permeability of NT was determined from the ratio of steady state flux (J) and 
amount of drug taken in the donor chamber (Cd) (Eq. (4)) (30,53). 
                     $%&&  '()	*+,∗./                                                          (4) 
Further, the enhancement ratio (ER) was determined from the ratio of flux (J) of natamycin from 
bilosomes (NB 2) or bilosome in situ gel (NBG 2) or transfersomes (FN 2 or FN 5) or 
transfersomes in situ gel (FNG 3) formulation and control formulation. 
2.2.15. Corneal Histology studies 
The corneal histological evaluation was performed on the corneas utilized in the in vitro 
transcorneal permeation studies. At the end of the study, corneas were fixed with 4% 
paraformaldehyde for 24 h, embedded in paraffin wax and were sliced into 5-μm cross sections 
using a microtome (American Optical® 820 Rotary Microtome). The tissue sections were mounted 
on a slide and dried overnight in an oven. The slide was washed with xylene to remove the paraffin 
and the tissue was hydrated by washing with alcohol and water. The tissue was stained with nuclear 
dye Gill III hematoxylin (StatLab medical) by rinsing for 10 min and later counterstained with 
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eosin. Finally, these slides were washed in running water, alcohol, and xylene. A cover slip was 
placed on the tissue section, examined under Nikon Eclipse 800 microscope and images were 
captured using PictureFrame 3.0 software (Optronics) to observe morphological changes in cornea, 
if any. 
2.2.16. Ocular distribution study 
The ocular distribution study was carried out in conscious male New Zealand albino rabbits. Prior 
to the study, the animals were allowed free access to food and water. The experiment was 
performed according to the approved protocols of the University of Mississippi Institutional 
Animal Care and Use committee and Association for Research in Vision and Ophthalmology 
(ARVO) statement. The rabbits were divided into 5 groups based on the formulation they were 
treated with and represented as control (Natacyn ®), NB 2, NBG 2, FN 2 and FNG 3 groups. 50 
µL of Natacyn ® or NB 2 or NBG 2 or FN 2 or FNG 3 formulation was topically administered in 
the cul-de-sac of the right eye of each rabbit in the corresponding group.  At the end of 2 h and 6 
h post treatment, rabbits (n=4) were anesthetized with intramuscular injection of ketamine and 
xylazine combination and euthanized with an excess amount of pentobarbital injected through a 
marginal ear vein. The treated eye was washed thoroughly with ice cold IPBS and enucleated 
immediately. The ocular tissues were carefully separated, weighed and stored at -80 °C until 
analysis.  
2.2.17. NT extraction from ocular tissue matrix 
Protein precipitation technique was employed for the extraction of NT from the ocular tissue 
matrix. Briefly, tissues such as cornea, sclera, iris ciliary (IC), retina-choroid (RC) were taken in 
separate Eppendorf tubes and cut into small pieces followed by the addition of 1 mL ice cold 
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methanol with 0.1% w/v formic acid to precipitate tissue proteins. The proteins in the aqueous 
humor (AH) (200 µL) and vitreous humor (VH) (500 µL) were precipitated by adding 200 µL and 
500 µL of ice-cold acetonitrile with 0.1% w/v formic acid respectively. All the Eppendorf tubes 
were vortexed for 30 seconds, allowed to stand at room temperature for 15 min and kept under 
sonication in bath sonicator (Fisher Scientiﬁc, USA) for 10 min to extract the drug into solvent. 
These samples were centrifuged at 13,000 rpm for 30 min, the supernatant was collected in the 
separate vials and stored at -80 oC until the analysis. The NT content in the supernatant solutions 
were estimated by injecting an aliquot of 100 µL into the HPLC operated with the chromatographic 
conditions described earlier (48). The column eluent was monitored at λmax (detection wavelength) 
of 304 nm using Waters 2487 Dual λ absorbance detector, and the sensitivity was set at 0.05 AUFS 
at room temperature. The NT was quantified using standard calibration plots constructed with the 
concentration range of interest in various ocular tissues. The limit of detection and quantiﬁcation 
in various ocular tissues were 10 and 20 ng/mL, respectively. The standard curves in all the ocular 
tissues were linear with a coefficient of determination (r2) ≥ 0.95. 
2.2.18. Statistical analysis 
The data obtained were subjected to one-way analysis of variance (ANOVA) and the statistical 
signiﬁcance of difference between formulations was calculated by Tukey’s post hoc HSD (version 
5.00; GraphPad Software, San Diego California). A ‘p’ value less than 0.05 was set to represent 
the statistically signiﬁcant difference. 
2.3. Results and Discussion 
NB and FN formulations were successfully fabricated by thin-film hydration technique coupled 
with probe sonication. Since the selection of vesicle forming components is critical to obtain the 
stable vesicles with high drug entrapment, S60 and PL were selected as vesicular components in 
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bilosomes and transfersomes, respectively (41-44). Earlier reports suggested the formation of 
small size niosomes, a nonionic surfactant vesicle, with S60 and stable liposomes with the 
phospholipon 90H (PL), due to the absence of unsaturated bonds in the fatty acid tails which leads 
to oxidation of phospholipid (42,54). 
2.3.1. Physicochemical properties of NB 
The physicochemical properties of bilosomes such as particle size (PS), polydispersity index 
(PDI), zeta potential (ZP) and drug entrapment (% EE) are dependent on the proportion of S60-to-
CH and the bile salt (ST) (45,55). Hence, in the present study, the influence of cholesterol and the 
bile salt on these parameters were investigated by varying the S60-to-CH molar ratio and ST 
quantity, respectively, keeping overall lipid content 250 µM. The NT content in all the NB 
Table 2.1: Composition and physicochemical properties of natamycin bilosomes (mean ± SD; n=3). 
Component/Evaluation 
parameter 
Formulation 
NB 1 NB 2 NB 3 NB 4 NB 5 NB 6 
Molar ratio (Span 
60:Cholesterol) 
2:1 1:1 1:2 2:1 1:1 1:2 
Span 60 (mg) 66 50 33 60 45 30 
Cholesterol (mg) 30 44 59 27 41 54 
ST (mg) 10 10 10 21 21 21 
PS (nm) 330.1 ± 21.6   235.0 ± 05.2  287.9 ± 12.1 380.4 ± 27.9 303.3 ± 16.0 348.2 ± 13.1 
PDI 0.30 ± 0.10 0.20 ± 0.01 0.23 ± 0.13 0.43 ± 0.23 0.28 ± 0.09 0.31 ± 0.03 
ZP (mv) -45.4 ± 4.5 -47.0 ± 1.5 -51.1 ± 3.3 -67.2 ± 2.6 -69.0 ± 1.5 -66.3 ± 9.1 
% EE 78.6 ± 4.1 93.7 ± 4.3 84.1 ± 2.6 70.1 ± 3.6 81.4 ± 2.5 74.1 ± 3.5 
Drug content (%) 96.7 ± 1.1 96.2 ± 2.0 96.1 ± 2.5 97.9 ± 4.1 90.1 ± 7.2 95.6 ± 1.2 
pH 6.2 ± 0.9 6.4 ± 0.3 6.3 ± 0.1 6.5 ± 0.2 7.1 ± 0.2 6.6 ± 0.3 
- NB and ST indicates natamycin loaded bilosomes and sodium taurocholate, respectively. 
- PS, ZP, PDI and % EE represents particle size, zeta potential, polydispersity index and % entrapment 
efficiency respectively. 
-  Total 250 µM of lipid mixture (including sodium taurocholate) was used in all preparations.  
- 10 mL of each formulation contains 10 mg of natamycin and 225 mg of glycerin. 
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formulations (pH 6.2 -7.1) was in the range of 90.1 ± 7.2% to 97.9 ± 4.1% (Table 2.1). The NB 
formulations showed PS ranging from 235.03 ± 05.29 nm to 380.43 ± 27.94 nm with a PDI of 0.20 
± 0.01-0.43 ± 0.23, ZP of -45.41 ± 4.54 mV - -69.03 ± 1.57 mV and % EE of 70.12 ± 3.66 % – 
93.75 ± 4.32 % (Table 2.1). 
2.3.2.1. Effect of cholesterol  
  
The PS and % EE of NT in bilosomes appeared to be dependent on the CH composition. It was 
noticed that the PS of bilosomes decreased as the CH content increased in the formulations (NB 1 
to NB 2 or NB 4 to NB 5) (Table 2.1). Generally, CH interacts with the hydrophobic tails of the 
lipids in the vesicle bilayer and controls the packing and rigidity of the vesicles (56). Thus, the 
decrease in PS can be attributed to the increased interactions of CH and S60 leading to close 
packing of the bilayers in the bilosomes. The % EE increased proportionately with the CH 
concentration in the formulations NB 1 to NB 2 or NB 4 to NB 5 suggesting effective intercalation 
of NT within the bilayer with increased hydrophobic interactions and reduced leakage of drug from 
rigid bilosomes (Table 2.1) (56,57). Interestingly, further increase in the CH concentration in the 
formulations (NB 3 or NB 6) resulted in higher PS and lower % EE (Table 2.1). This can be 
attributed to the perturbation of bilayer structure by the accommodation of excess cholesterol and 
thereby leading to the expulsion of drug from the vesicles (55,57). 
2.3.2.2. Effect of bile salt  
Consistent with the earlier reports, the PS, PDI, ZP and % EE of the bilosomes were influenced 
by the amount of bile salt (40,45,58). With a steroid like structure, ST, a salt of taurocholic acid 
(bile acid), resides in the bilayer of the bilosomes imparting negative ZP due to its anionic nature 
(44,58). The PS, PDI and ZP of the formulations with 40 µM (21 mg) ST (NB 4 – NB 6) were 
higher compared to the bilosomes with 20 µM (10 mg) ST (NB 1- NB 3), at similar molar ratio of 
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S60 and CH (Table 2.1). These results corroborate with earlier literature reports which 
demonstrated the increased PS and PDI because of the repulsion between the bilayers of the 
vesicles due to the greater negative charge (ZP) at higher concentration of ST (59). Moreover, the 
accommodation of extra ST in the bilayers can increase the bulkiness of bilosomes resulting in 
increased particle size and the excess of amount of ST forms micelles in the dispersion medium 
thereby resulting in increased PDI (60,61). Strikingly, the %EE of NT in the bilosomes, with same 
molar ratio of S60 and CH, decreased with the increased ST quantity (Table 2.1). This drop in 
%EE, at higher concentration of ST, is attributed to the leakage of the entrapped drug from the 
bilosomes owing to the fluidization of vesicle bilayer by bile salt micelles (44).  
 The NB 2 formulation showed uniformly distributed bilosomes (235.0 ± 05.2 nm) in the 
colloidal dispersion (PDI: 0.20 ± 0.01) with negative ZP (-47.0 ± 1.5 mV), and higher % EE (93.7 
± 4.3 %). Additionally, TEM image revealed layered nanoparticles confirming the vesicular 
structure of the bilosomes in the NB 2 formulation (Fig. 2.1A). Hence, this formulation was 
optimized and used in further investigations and for the preparation of in situ gel formulations. 
 
Fig. 2.1: Transmission electron micrographs (TEM) depicting the layered morphology of bilosomes in A) 
NB 2 and B) NBG 2 and transfersomes in C) FN 2 and D) FNG 3. 
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2.3.2. Physicochemical properties of FN 
The impact of phospholipid and the TPGS on natamycin transfersomes PS, PDI, ZP and % 
EE were investigated by varying the PL-to-S60 molar ratio and T quantity, respectively, keeping 
overall lipid content 250 µM. The NT content in all the FN formulations (pH 6.1 -6.9) was in the 
range of 94.7 ± 7.2% to 97.9 ± 4.1% (Table 2.2). 
 The FN formulations showed PS ranging from 137.3 ± 3.0 nm to 192.1 ± 8.6 nm with a 
PDI of 0.20 ± 0.01-0.41 ± 0.1, ZP of -13.2 ± 2.6 mV - -20.9 ± 3.7 mV and % EE of 69.4 ± 2.4 % 
– 91.4 ± 2.7 % (Table 2.2). 
It was noticed that the PS, PDI and % EE of NT in transfersomes were influenced by the molar 
ratio of PL:S60. The FN obtained from equimolar composition of PL and S60 (FN 2 and FN 5) 
Table 2.2: Composition and physicochemical properties of natamycin transfersomes (mean ± SD; n=3). 
Component/Evaluation 
parameter 
Formulation 
FN 1 FN 2 FN 3 FN 4 FN 5 FN 6 
Molar ratio 
(Phospholipon 
90H:Span60) 
2:1 1:1 1:2 2:1 1:1 1:2 
Phospholipon 90H 
(mg) 
91 122 136 82 109 123 
Span60 (mg) 52 36 27 46 31 23 
T (mg) 10 10 10 50 50 50 
PS (nm) 192.1 ± 8.6 145.2 ± 2.9 165.2 ± 2.9 171.4 ± 3.9 137.3 ± 3.0 158.2 ± 6.1 
PDI 0.33 ± 0.12 0.20 ± 0.01 0.21 ± 0.1 0.41± 0.1 0.32 ± 0.01 0.40 ± 0.3 
ZP (mv) -14.4 ± 2.4 -17.0 ± 1.5 -20.9 ± 3.7 -13.2 ± 2.6 -15.3 ± 1.5 -18.3 ± 3.1 
% EE 74.1 ± 4.2 84.8 ± 4.8 69.4 ± 2.4 80.7 ± 1.3 91.4 ± 2.7 75.4 ± 1.5 
Drug content (%) 94.7 ± 2.2 95.2 ± 1.6 97.1 ± 3.0 98.1 ± 1.1 98.3 ± 2.3 95.6 ± 1.2 
pH 6.3 ± 0.4 6.1 ± 0.7 6.9 ± 0.1 6.2 ± 0.5 6.1 ± 0.4 6.9 ± 0.1 
 - FN and T indicates natamycin loaded transfersomes formulation and TPGS, respectively. 
- PS, ZP, PDI and % EE represents particle size, zeta potential, polydispersity index and % entrapment 
efficiency respectively. 
-  Total 250 µM of lipid mixture was used in all preparations.  
- 10 mL of each formulation contains 10 mg of natamycin and 225 mg of glycerin. 
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were small compared to those resulted from 2:1 and 1:2 molar proportion (Table 2.2).  This could 
be attributed to the stronger hydrophobic interactions between the nonionic surfactant (S60) and 
fatty acid chains of phospholipid (PL) in the vesicle bilayer which determines the critical packing 
of the vesicles (39). The higher % EE of NT in transfersomes with equimolar proportion of PL and 
S60 (FN 2 or FN 5) suggested the effective intercalation of NT within the bilayer with increased 
hydrophobic interactions leading to closely packed transfersomes with no or low drug leakage 
(Table 2.2) (39,40). The higher PS and lower % EE of transfersomes obtained from 2:1 and 1:2 
molar proportion of P and S60 could be due to either low hydrophobic interactions between 
vesicular components leading to poor packing of the bilayers or the perturbation of bilayer 
structure by the accommodation of excess of P and thereby leading to the expulsion of drug from 
the vesicles (39,40). Interestingly, the proportion of edge activator (T) in the structure of 
transfersomes influenced the PDI and % EE, but not PS and ZP, of these vesicles (Table 2.2). At 
any given molar proportion of PL:S60, the EE and PDI of the transfersomes increased with 
increase in the amount edge activator (T) (table 2.2). This higher EE could be due to the formation 
drug entrapped micelles by the excess amount of T that leaked into the dispersion medium from 
bilayer of the transfersomes and, thereby resulted in increased PDI (43,44).  
 The FN 2 (145.2 ± 2.9 nm) and FN 5 (137.3 ± 3.0 nm) formulations showed uniformly 
distributed transfersomes in the colloidal dispersion (PDI: 0.20 ± 0.01) with higher % EE ((FN 2-
84.8 ± 4.8 %)- FN 5 (91.4 ± 2.7 %)). Additionally, TEM image revealed layered nanoparticles 
confirming the vesicular structure of the transfersomes in the FN 2 formulation (Fig. 2.1C).  
2.3.3. Evaluation of NB and FN in situ gel formulations 
 
The NB in situ hydrogel systems (NBG/NBX) were derived by introducing the NB 2 formulations 
into the solution comprising gellan gum/xanthum gum, anionic polysaccharide polymers, as ion 
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sensitive gelling agents. Similarly, the FNG formulations were prepared by incorporating FN 2 
preparation into the solution with gellan gum. The physiochemical properties of bilosomes in the 
in situ gel formulations (NBG and NBX) were similar to NB 2 preparation, and the properties of 
transfersomes in the FNG formulations were no different to the FN 2 preparation, confirming no 
interactions of gelling agents with vesicular systems. Several literature reports have successfully 
demonstrated the formulation of nanoparticles or nanoemulsion loaded in situ gels using these 
gelling agents as they crosslink in the presence of electrolytes to form hydrogel matrix with higher 
pore size facilitating the movement of nanoparticles through the gel (26,35-39). The tested 
concentrations of gelling agents were below the limits specified in the inactive ingredients database 
from US FDA (62). Owing to the thickening property of gellan gum and xanthum gum, it is 
essential to measure the viscosity of the in situ gel preparations as it determines the free flow of 
the formulation from the container ensuring the ease of administration. A viscosity of 25-50 cP is 
most common for ophthalmic solutions (63). The formation, residence time, viscoelastic behavior 
and adhesive property of the hydrogels are critical parameters in deciding the pre-corneal residence 
and shear thinning pseudoplastic behavior for comfort in the eye while blinking (27,35,37). 
However, these parameters depend on the kind of gelling agent. Hence, this study focused on the 
influence of the two most commonly used ion sensitive gelling agents on the critical properties of 
in situ gel formulations.  
2.3.3.1. Impact of type of gelling agent 
 
The evaluation parameters of the bilosomes in situ gel formulations (NBG and NBX) and 
transfersomes in situ gel systems (FNG) are represented in the Table 2.3 and Table 2.4, 
respectively. The viscosity of the formulations (NBG or NBX) increased with the concentration of 
gelling agents confirming their thickening property (Table 2.3). At any given concentration of 
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gelling agent, the viscosity of the NBG formulations were lower compared to that observed in 
NBX formulations (Table 2.3). These results were in accordance with the previous reports 
explaining the higher viscosity of the xanthan gum due to the formation of helical structures via 
hydrogen bonding resulting in the immobilization of water (64). Additionally, the increased 
intermolecular accumulation of polymer chains because of the high molecular weight of xanthan 
gum (~ 2000K Daltons) could be the reason for high viscosity of NBX systems (65). Conversely, 
the lower viscosity of the gellan gum formulations (NBG) can be attributed to the formation of 
weak double helices associated with the van-der-Waal forces (37). The NBG formulations 
immediately (< 5 sec) underwent in situ phase transition and formed hydrogels while the NBX 
formulations slowly (≥ 20 sec) formed in situ hydrogels in the STF suggesting the slow or poor 
interaction of electrolytes with the xanthan gum compared to the gellan gum (37) (Table 2.3). The 
Table 2.3: Composition and characterization of NB in situ hydrogel formulations (mean ± SD; n=3). 
Component/Evaluat
ion parameter 
Formulation 
NB 2 NBG 1 NBG 2 NBG 3 NBX 1 NBX 2 NBX 3 
Molar ratio (Span 
60:Cholesterol) 
1:1 1:1 1:1 1:1 1:1 1:1 1:1 
Span 60 (mg) 50 50 50 50 50 50 50 
Cholesterol (mg) 44 44 44 44 44 44 44 
ST (mg) 10 10 10 10 10 10 10 
G (mg) -- 20 30 40 -- -- -- 
X (mg) -- -- -- -- 20 30 40 
Viscosity (cP) 
(Formulation) 
17.1 ± 2.7 24.7 ± 1.5 37.5 ± 2.4 68.3 ± 3.2 39.5 ± 4.1 87.8 ± 2.5 124.2 ± 4.7 
GT (sec) -- < 5 < 5 < 5 > 20 > 20 15-20 
GRT (h) -- 3-4 6-8 >12 <1 1-2 5 
Viscosity (cP) 
(hydrogel) 
-- 104.5 ± 1.5 514.9 ± 3.8 1285. 6 ± 6.8128.9 ± 6.5 220.3 ± 5.7410.6 ± 4.2   
Work of Adhesion 
(g. sec) 
-- 0.80 ± 0.01 1.39 ± 0.06 1.31 ± 0.07 0.68 ± 0.02 0.71 ± 0.01 1.14 ± 0.10 
- NB, NBG, NBX, ST, GT and GRT represents natamycin loaded bilosomes, natamycin bilosome in situ gels 
with gellan gum, natamycin bilosome in situ gels with xanthum gum, gel formation time and intact gel 
residence time and sodium taurocholate, respectively. 
-  Total 250 µM of lipid mixture (including sodium taurocholate) was used in all preparations.  
- 10 mL of each formulation contains 10 mg of natamycin and 225 mg of glycerin. 
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intact gel residence time and the viscosity of the hydrogels increased with the increasing proportion 
of the gelling agent (Table 2.3). However, at a given concertation of the gelling agent, these 
properties were higher for the hydrogels formed from NBG formulations compared to that from 
NBX preparations (Table 2.3). Similar findings have been reported in the literature where higher 
viscosities/stiffness of the gellan gum based in situ gels was due to the cross-linking of the polymer 
chain by the mono/divalent cation mediated aggregates of double helices (66). In contrast, the 
lower viscosity/intactness of the hydrogel formed from the NBX formulations can be attributed to 
the presence of the trisaccharide side chain in the branched structure of xanthan gum which avoids 
the cation triggered helix formation leading to low or no cross linking of the polymer (26). The 
adhesiveness of the in situ hydrogel is an important factor that determines its contact with the 
corneal or scleral surface (38). In this study, the work of adhesion of hydrogels was measured to 
understand their adhesive characteristics. The work of adhesion increased with respect to the 
concentration of gel forming agent in NBX but similar trend in NBG formulations were seen up 
Table 2.4: Composition and characterization of FN in situ hydrogel formulations (mean ± SD; n=3). 
Component/Evaluation 
parameter 
Formulation    
FN 2 FNG 1 FNG 2 FNG 3 
Molar ratio (Phospholipid 
90H:Span60) 
1:1 1:1 1:1 1:1 
Phospholipid 90H (mg) 122 122 122 122 
Span60 (mg) 36 36 36 36 
T (mg) 10 10 10 10 
G (mg) -- 10 20 30 
Viscosity (cP) 
(Formulation) 
16.8 ± 3.1 18.7 ± 1.5 27.5 ± 1.4 39.6 ± 2.6 
GT (sec) -- < 5 < 5 < 5 
GRT (h) -- < 1 3-4 6-7 
Viscosity (cP) 
(hydrogel) 
-- 94.1 ± 2.5 206.9 ± 4.1 651.3 ± 1.7 
Work of Adhesion (g. sec) -- 0.56 ± 0.05 0.94 ± 0.02 1.33 ± 0.04 
- FN, FNG, T, GT and GRT represents natamycin loaded transfersomes, natamycin transfersomes in situ gels 
with gellan gum, TPGS, gel formation time and intact gel residence time, respectively. 
-  Total 250 µM of lipid mixture was used in all preparations.  
- 10 mL of each formulation contains 10 mg of natamycin and 225 mg of glycerin. 
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to the gellan gum concentration of 0.3% w/v. This might be due to the formation of stiff gel with 
poor shear thinning behavior, at higher proportion of gellan gum (0.4 %), which could lead to 
discomfort in the eye (37). At a given concentration of gelling agent, it was noticed that the work 
of adhesion of hydrogels from NBG formulations was high over that from NBX formulations 
(Table 2.3). These findings agree with the measured viscosities of the hydrogels and could be 
attributed to the structure related differences in cross-linking of the polymer chains of gellan and 
xanthan gum (37,64). These results exemplified the superior in situ gelling features of gellan gum, 
over xanthan gum. Thus, gellan gum based FN in situ gel systems were further studied. As 
observed with the NBG formulations, the FNG formulations showed increasing in situ gelling 
behavior (GT), intact gel residence time (GRT), rheological properties (viscosity of FNG 
formulations and their corresponding in situ hydrogels), and adhesive properties with increase in 
the composition of gellan gum (Table 2.4).  
Thus, NBG 2 and FNG 3 formulations which showed acceptable viscosity (37.5 ± 2.4 cp and 39.6 
± 2.6 cp, respectively), immediate transition into a hydrogel in the STF which remained intact for 
> 6h with superior adhesive property were selected as suitable NB and FN in situ gel systems and 
investigated further. Layered nanoparticles seen in the STF with hydrogel suggested that the in 
situ gels system did not alter morphometric properties of bilosomes and or transfersomes (Fig. 2.1 
B and C). 
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2.3.4. Fourier transmission infrared spectroscopy (FTIR) 
 
The FTIR spectra of NT, NBG 2 and FNG 3 formulations and other excipients are portrayed in 
Figure 2.2. The existence of signature functional group stretching of NT at 3260 cm-1 (NH+3 
deformation), 1713 cm-1 (-C=O), 1567 cm-1 (-CH=CH-) and 1266 cm-1 (-C-O-C-) in the FTIR 
spectra of NBG 2 and FNG 3 formulations suggested no drug-excipient chemical interactions. 
However, the slight shift in the IR bands of NT in NBG 2 and FNG 3 spectra could be due to the 
transformation in NT physical state (Fig 2.2).  
2.3.5.  In vitro cytotoxicity 
 
The cytotoxicity of NB 2, FN 2, FN 5, NBG 2 and FNG 3 formulations in HCLE cells is presented 
in Figure 2.3. About 100.5 ± 4.5, 110.7 ± 5.6 and 93.0 ± 6.7 % cell viability was noticed for NB 
 
Fig. 2.2: FTIR spectra of A) sodium taurocholate, B) cholesterol, C) span 60, D) phospholipon 90H, E) TPGS, F) 
natamycin, G) NBG 2 and H) FNG 3. 
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2, NBG 2 and FNG 3 groups, respectively, which were not statistically different from the negative 
control group (saline) (Fig. 2.3). The results noted from FN 2 and FN 5 formulations were 
significantly different from that observed in negative control group (saline). The positive control 
group treated with triton X 100 (1 %), a nonionic surfactant, showed 6.9 ± 2.5 % cell viability (Fig. 
2.3). Hence, the drop in % cell viability of the groups exposed to FN formulations (FN 2 and FN 
5) could be related with the overall nonionic surfactant (NS) composition (T and S60) in 
formulations. The group treated with FN 2 (0.45 % w/v of NS) showed considerably higher % cell 
viability (65.7 ± 4.8%) compared to FN 5 (0.86 %w/v of NS) (17.7 ± 5.4%) (Fig. 2.3). Hence, it is 
presumed that the higher NS concentration might have attributed to lower % cell viability. 
However, no reports in the literature has demonstrated the corneal toxicity of the combination of 
S60 and T. The higher % cell viability of FNG 3 group suggested that the in situ gels of FN 2 
formulations are well tolerated by corneal epithelial cells (Fig. 2.3). Hence, the cytotoxicity results 
of NB 2 and NBG 2 formulations suggest that the optimized bilosomes and its in situ gel 
Fig. 2.3: Cytotoxicity profile of NB 2, FN 2, FN 5, NBG 2 and FNG 3 formulations in HCLE cells (mean ± 
SEM; n=6). 
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formulations are well tolerated by corneal epithelial cells and can be explored as a suitable vehicle 
for topical ocular drug delivery. Similar literature reports discussed no ocular cytotoxicity with the 
vesicular systems containing nonionic surfactants (S60) and/or bile salts (44,55). In addition, a 
study outlined no corneal cytotoxicity with the liposomes containing the sodium taurocholate, 
whereas formulations containing sodium deoxycholate were toxic to HCE cells (58). In the 
cytotoxicity studies, the HCLE cells were exposed to the formulations for 24h. But, most of the 
topical ophthalmic formulations will be in contact with cornea for short time due to rapid clearance 
from the precorneal space. Thus, to further understand the toxic effects of bilosomes and 
transfersomes on cornea anatomy, histology studies were performed on the corneas exposed to the 
formulations in corneal transport studies. 
2.3.6. Corneal transport studies 
 
The saturation solubility of NT was in the following order: DPBS (2.5 % w/v RMβCD) > DPBS 
≥ IPBS > water. Hence, to maintain sink, DPBS (2.5 % w/v RMβCD) was utilized as the release 
 
Fig. 2.4: In vitro transcorneal A) flux and B) apparent permeability coefficient (Papp) of natamycin from control, 
bilosomes, bilosomes in situ gel, transfersomes and transfersomes in situ gel formulations (mean ± SD; n=3). *-
significantly different from control (p<0.05); ¥-significantly from any formulations group (p<0.05). 
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medium in the in vitro corneal transport studies. The transcorneal permeability parameters of NT 
from control, NB 2, FN 2, FN 5, NBG 2 and FNG 3 formulations are detailed in Figure 2.4. A 
significant improvement in the transcorneal flux of drug was observed from NB 2, FN 2, FN 5, 
NBG 2 and FNG 3 over that from control suspension (p<0.05) (Fig. 2.4A). An ER of 9.01 and 
6.37 transcorneal flux of NT from NB 2/FN 2 and NBG 2/FNG 3 formulations, respectively, 
indicated their potential to improve the corneal transport of NT. Further, significantly higher 
apparent permeability coefficient (Papp) of NT from NB 2, FN 2, NBG 2 and FNG 3, compared to 
control, could be attributed to the improved permeability of these advanced vesicles (p<0.05) (Fig. 
2.4B)). These findings verify the previous literature reports, which described the penetration of 
bilosomes or transfersomes through intact cornea owing to the fluidization of corneal lipids 
(44,58,42,43). In addition, the superior flexibility of these vesicles with bile salt (ST) and edge 
activator (T) enables them to permeate across the intact biological membranes (40-43). The lower 
transcorneal flux and Papp of NT from NBG 2, compared to NB 2, were consistent with the earlier 
reports which suggested the slower release of drug loaded nanoparticles or vesicles from the in 
situ hydrogel matrix (p<0.05) (Fig. 2.4) (36,37).   
 Interestingly, an ER of ~16 fold transcorneal flux of NT from the FN 5 formulation was 
seen with apparent permeability coefficient (Papp) 3.9 X 10-5 Cm/s (Fig. 2.4). These results were 
significantly superior over those observed from any other formulations (p<0.05). A sudden 
increase in the % cumulative drug release, from FN 5 formulation, was noticed after 1h timepoint 
(data not shown). These findings suggest that there might be a damage to the corneal structure.  
2.3.7. Corneal histology 
  
Corneal histology studies were carried out to access the corneal tissue architecture after the 
treatment with NB 2, FN 2, FN 5, NBG 2 and FNG 3 formulations. The histology of corneas 
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exposed to DPBS, marketed suspension, NB 2 FN 2, FN 5, NBG 2 and FNG 3 in the in vitro 
transcorneal permeation studies are portrayed in Figure 2.5. Normal anatomy of an intact cornea 
represents epithelial layer (EP) and stroma layer (SL) separated by Bowman’s membrane (BM), 
and descemet’s membrane that separates the stroma from endothelial layer. Any observations like 
tear or loss, degeneration or disappearance of epithelial layer, separation of Bowman’s membrane 
from epithelial and stroma layers, vacuoles in the stroma layer confirms the damage of corneal 
structure. In this study, the corneas exposed to NB 2, FN 2, NBG 2 and FNG 3 formulations did 
not show any such signs, suggesting no alterations in the corneal tissue architecture during the in 
vitro transcorneal permeability studies (Fig. 2.5). Moreover, the corneas exposed to NB 2, FN 2, 
NBG 2 and FNG 3 formulations were not structurally different from those exposed to control 
marketed suspension and DPBS (Fig. 2.5) suggesting the corneal compatibility of these advanced 
Fig. 2.5: Histology images of rabbit corneas exposed to A) DPBS, B) control, C) NB 2, D) NBG 2, E) FN 2, F) FN 
5, and G) FNG 3 formulations. EP-epithelial layer; BM-Bowman’s membrane; SL- stromal layer. 
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vesicular systems and their corresponding ion sensitive in situ gel formulations. Similar findings 
were reported in the literature which indicated safety of ST and/or nonionic surfactant based 
vesicles to ocular sites (37,55,58,42,43).     
 The loss of epithelial layer on the cornea exposed to FN 5 formulation confirmed that the 
transfersomes, prepared with 0.8 % w/v of NS (T and S60), is toxic to the corneal structure and, 
hence, showed superior transcorneal permeability characteristics (Fig. 2.5F). These results 
corroborate with the observations in the in vitro cytotoxicity studies (Fig. 2.3). Hence, NB 2, FN 
2, NBG 2 and FNG 3 formulations were selected for the in vivo performance evaluation.  
2.3.8. Ocular disposition studies 
 
Since the performance of pharmaceutical product depends on the drug and other excipients in it, 
undiluted Natacyn suspension (5 % w/v natamycin) was used, to exclude the underestimation of 
the product efficacy, as a control formulation in the ocular distribution studies. The amount of drug 
observed in the ocular tissues of the rabbits at the end of 2h and 6h post treatment with control, 
NB 2, FN 2, NBG 2 and FNG 3 formulations are given in table 2.5. To understand the permeability 
and prolong delivery of NT from control, NB 2, FN 2, NBG 2 and FNG 3formulations, the mean 
dose normalized drug levels in the rabbit ocular tissues were calculated and presented in Figure 
2.6.     
 At the end of 2h, the concentration of NT observed in the cornea and AH of rabbits 
administered with control at 50-fold high dose were disproportionately higher by ~13-18 and ~3-
6-fold, respectively, compared to that treated with NB 2, FN 2, NBG 2 and FNG 3 formulations 
(Table 2.5). Hence, the mean dose normalized NT concentration in cornea and AH of rabbits 
treated with NB 2, FN 2, NBG 2 and FNG 3 formulations were significantly higher, over that seen 
in the control group, indicating the improved penetration of 
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NB’s and FN’s across the cornea (p<0.05) (Fig. 2.6A). These results support the findings from 
corneal transport studies and could be attributed to the intercalation of bilosomes or transfersomes 
with corneal lipids, and their amphiphilic nature, due to the presence of bile salt (ST) or edge 
activator (T), driving them to hydrophilic AH (37,67). In contrast, the lipophilic character might 
have led the drug, in the cul-de-sac from control suspension (higher amount), to partition into 
corneal epithelial cells resulting in high corneal drug levels, however, the poor aqueous solubility 
could have limited the penetration through hydrophilic stroma layer in cornea leading to low dose 
normalized AH drug concentration. Unlike seen in the cornea, sclera is 10-fold more permeable to 
hydrophilic drugs, but it still is impervious to lipophilic molecules (68,69). Thus, the actual amount 
of NT in rabbit sclera from control group treated with 50-fold high drug dose was 
disproportionately higher by ~6-7 and ~10-12 fold higher over that noted in NB 2, FN 2, NBG 2 
and FNG 3 group, respectively, confirming the limited scleral permeation of NT from marketed 
suspension (Table 2.5). The significantly higher mean dose normalized NT level in sclera of 
rabbits treated with NB 2, FN 2, NBG 2 and FNG 3 formulations, compared to that noticed in the 
control group, exemplifies the ability of bilosomes and transfersomes as the potential vehicles to 
reduce the scleral barrier characteristics (p<0.05) (Fig. 2.6A). The amount of NT in the IC of 
rabbits from all the treatment groups could be attributed to the permeation of drug into the ciliary 
body through cornea-scleral limbus junction (29,30) (Table 2.5). The mean dose normalized IC 
NT levels were significantly higher in the rabbits treated with NB 2, FN 2, NBG 2 and FNG 3 
formulations, compared to that treated with control suspension, which could be attributed to the 
transcytosis/endocytosis of these advanced vesicles, through corneal/scleral epithelial cells into 
the IC (p<0.05) (Fig. 2.6A) (37,58). As expected, the mean dose normalized drug levels in cornea, 
AH, IC and sclera of rabbits administered with NB 2 and FN 2 formulation were significantly 
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higher compared to that treated with their corresponding in situ gel systems which could be due to 
the slow release of bilosomes and/or transferosomes from the in situ hydrogel matrix (44,47) 
(p<0.05) (Fig. 2.6A). The drug levels in the RC and the VH of rabbits from all the treatment groups, 
except FN 2 group, were below the detection limit (Table 2.5 & Fig. 2.6). Interestingly, the mean 
dose normalized drug levels in IC, sclera and RC of the rabbits treated with FN 2 formulation were 
significantly different from that observed in the rabbits in any other groups which could be 
attributed to the flexibility of the transfersomes, imparted by the edge activator (TPGS) that helps 
distribute them into scleral surface and thereby, diffuse into RC (42,43).  
 At the end of 6h, no detectable drug levels were noticed in any of the ocular tissues, except 
sclera, in the rabbits treated with NB 2 and FN 2 indicating the clearance of the formulation from 
the precorneal space (Table 2.5 & Fig. 2.6B). Surprisingly, the cornea, the IC and the sclera of 
rabbits from the control group showed some drug levels that could be attributed to depo formation 
of drug in the cornea and sclera (Fig. 2.6B). The undetectable drug levels in the AH, the RC and 
the VH in these rabbits, however, confirmed no or low drug in the cul-de-sac and poor 
transcorneal/transscleral penetration of NT (Fig. 2.6B). These results agree with a study which 
reported poor NT levels (< 0.8 µg/mL) in the rabbit tear at 5h post topical administration of 
marketed suspension (47). In contrast, significantly higher mean dose normalized drug levels in 
all the ocular tissues, except VH, in the rabbits topically administered with NBG 2 and FNG 3 
formulations confirmed improved pre-corneal residence time of the in situ hydrogel of NT 
bilosomes and transfersomes (Fig. 2.6B). As reported earlier, in situ hydrogels bond with 
glycoprotein moieties of the epithelial cells through hydrophobic interactions/van der Waals 
forces/ionic/hydrogen bonding and facilitates higher mucoadhesion with the biological 
membranes ensuring longer residence time (70). These results confirmed the ability of ion-
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sensitive in situ hydrogels of these advanced vesicles, bilosomes and transfersomes, as potential 
platforms for improved and prolong ocular drug delivery.  
2.3.9. Stability Studies  
The physical stability of the optimized formulations at 4°C and 25°C are specified in Table 2.6 and 
Table 2.7. The PS, PDI, ZP and % EE of NB 2 and FN 2 formulations stored at 25°C were not 
statistically different for 30 days but changed significantly by 60 days, with respect to those 
observed initially (p<0.05) (Table 2.6 and Table 2.7). This could be due to the aggregation of these 
vesicles with the leakage of drug. Surprisingly, the physicochemical properties of the NBG 2 and 
Table 2.6: Physical stability of optimized natamycin bilosomes and bilosome in situ gel formulations stored at 
4°C and 25°C for 60 days (mean ± SD; n=3). 
Formulation 
Stored 
at 
Time 
(days) 
PS (nm) ZP (mv) PDI % EE 
Drug 
content (%) 
NB 2 
Initial 235.0 ± 5.3 -47.0 ± 1.6 0.20 ± 0.01 93.8 ± 4.3 99.2 ± 2.0 
4°C 
30 239.3 ± 4.4 -44.6 ± 3.9 0.21 ± 0.01 91.5 ± 1.2 98.4 ± 1.0 
60 243.6 ± 5.9 -45.7 ± 2.0 0.21 ± 0.01 91.4 ± 4.6 98.5 ± 1.3 
25°C 
30 240.7 ± 3.7 -44.6 ± 3.2 0.21 ± 0.02 92.4 ± 2.2 98.4 ± 1.2 
60  264.2 ± 10.9* -44.2 ± 4.7 0.28 ± 0.04* 81.9 ± 1.9* 97.9 ± 2.0 
NBG 2 
Initial      234.3 ± 6.1 -48.0 ± 1.5 0.22 ± 0.07 90.5 ± 1.2 98.9 ± 1.7 
4°C 
30 236.7 ± 6.9 -46.8 ± 0.4 0.21 ± 0.02 90.5 ± 0.3 98.4 ± 1.5 
60 244.4 ± 8.4 -46.7 ± 0.9 0.22 ± 0.01 90.4 ± 1.2 98.3 ± 1.9 
25°C 
30 240.4 ± 3.4 -47.5 ± 4.2 0.22 ± 0.01 89.7 ± 2.3 98.0 ± 1.9 
0 
245.4 ± 10.4 -46.7 ± 6.2 0.29 ± 0.16  81.9 ± 1.2 97.9 ± 0.5 
- NB, NBG, PS, ZP, PDI and % EE represents natamycin bilosomes, natamycin bilosome in situ gel 
formulation, particle size, zeta potential, polydispersity index and % entrapment efficiency respectively. 
-*- indicates significant difference (p<0.05) between the NB 2 or NBG 2 at 25 oC for 60 days and fresh NB 2 or 
NBG 2 at initial conditions (day 0 at room temperature). 
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FNG 3 formulations did not differ upon storage at 25°C for 60 days which could be attributed to 
the viscosity limited migration and aggregation of bilosomes and/or transfersomes (Table 2.6 and 
Table 2.7). No variations in the PS, PDI, ZP and % EE of all the optimized formulations stored at 
4°C for 60 days suggests that these preparations can be stored at refrigerated conditions (4°C) 
(Table 2.6 and Table 2.7).   
2.4. Conclusion 
 
NT bilosomes (NB), corresponding in situ gel systems, NT transfersomes and corresponding in 
situ gel systems were successfully fabricated and evaluated. The NB and FN formulation with 
equimolar ratio of vesicular components and low amount of bile salt (ST) or edge activator (T) 
resulted in uniformly distributed small size vesicles with higher drug % EE.  The optimized NB 
Table 2.7: Physical stability of optimized natamycin transfersomes and transfersomes in situ gel formulations 
stored at 4°C and 25°C for 60 days (mean ± SD; n=3). 
Formulation 
Stored 
at 
Time 
(days)
PS (nm) ZP (mv) PDI % EE 
Drug 
content (%) 
FN 2 
Initial 145.3 ± 2.9 -20.0 ± 1.5 0.20 ± 0.01 84.8 ± 4.8 95.2 ± 1.6 
4°C 
30 146.2 ± 3.4 -19.4 ± 3.9 0.23 ± 0.02 82.4 ± 1.6 97.3 ± 2.0 
60 148.4 ± 4.2 -18.6 ± 1.3 0.22 ± 0.02 80.4 ± 3.6 94.5 ± 3.3 
25°C 
30 149.0 ± 3.7 -16.4 ± 2.4 0.25 ± 0.01 83.1 ± 3.2 96.4 ± 2.1 
60  164.5 ± 10.9* -12.2 ± 1.7* 0.38 ± 0.02* 81.9 ± 1.9* 97.9 ± 2.0 
FNG 3 
Initial      148.9 ± 2.1 -18.1 ± 3.5 0.22 ± 0.01 87.5 ± 3.2 98.9 ± 1.7 
4°C 
30 149.7 ± 2.3 -17.8 ± 1.4 0.21 ± 0.01 86.5 ± 1.3 97.1 ± 2.5 
60 150.2 ± 4.4 -16.7 ± 2.4 0.27 ± 0.07 86.4 ± 2.2 98.1 ± 3.1 
5°C 
30 151.4 ± 4.1 -17.5 ± 2.2 0.25 ± 0.01 84.3 ± 3.7 96.2 ± 3.9 
60 157.2 ± 9.3 -16.7 ± 6.2 0.29 ± 0.11  82.9 ± 4.2 98.1 ± 6.5 
- FN, FNG, PS, ZP, PDI and % EE represents natamycin transfersomes, natamycin transfersomes in situ 
gel formulation, particle size, zeta potential, polydispersity index and % entrapment efficiency respectively. 
- *- indicates significant difference (p<0.05) between the FN 2 or FNG 3 at 25 oC for 60 days and fresh FN 
2 or FNG 3 at initial conditions (day 0 at room temperature). 
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and FN loaded in situ gel (NBG and FNG) systems with 0.3 % w/v gellan gum rapidly transformed 
into hydrogel in the STF, which displayed good viscoelastic and adhesive properties. The 
cytotoxicity and corneal histology evaluations confirmed compatibility and safety of the bilosomes 
formulations on ocular tissues. These studies also revealed that the transfersomes prepared with 
0.45 % w/v nonionic surfactants (NS) were safe and compatible for ocular drug delivery but, the 
transfersomes obtained with 0.8 % w/v NC induced corneal toxicity causing damage to the 
structure of the cornea. The in vitro corneal transport studies confirmed the superior permeability 
characteristics of NT from the optimized bilosomes and transfersomes (0.45% w/v NS) 
formulations, over control suspension. Furthermore, considerably higher mean dose normalized 
drug levels in the ocular tissues from NBG and FNG formulations for 6h, compared to that from 
the control suspension, demonstrated the effectiveness of ion-sensitive in situ hydrogels of 
bilosomes and transfersomes as the potential carrier systems for the improved and prolonged 
topical ocular drug delivery. Nevertheless, the ocular distribution studies of NT from NBs and FNs 
with higher drug loads is necessary to confirm the efficiency of these systems as suitable vehicle 
for enhanced ocular drug delivery platforms. 
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CHAPTER 3 
EFFLUX PROTEINS ON THE BLOOD OCULAR BARRIERS REGULATE OCULAR 
DELIVERY OF CHEMOTHERAPEUTIC AGENTS: IMPACT OF SPECIFIC INHIBITORS 
 
3.1. Introduction 
The delivery of therapeutics into the deeper ocular tissues via the systemic route remains a 
challenge due to the presence of complex blood ocular barriers (BOB). The BOB comprises of the 
blood-aqueous barrier (BAB), formed by the epithelial cells of the iris-ciliary bodies, and the 
blood-retinal barrier (BRB), made up of the endothelial cells of the retinal blood vessels and the 
retinal pigmented epithelium (RPE) (3,4,71-73). The tight-junction proteins and the efflux proteins 
present in the BAB and BRB protect the anterior and posterior segment ocular tissues by 
preventing the paracellular and/or transcellular transportation of endobiotics and xenobiotics 
(3,4,74,75). 
In the recent past, numerous researchers have investigated the impact of efflux transporters 
on the permeability of hydrophobic anticancer and other drugs across various blood-organ barriers 
(71-73). In this regard, the most common efflux proteins are P-glycoprotein (P-gp) and multidrug 
resistance protein (Mrp), major efflux proteins belonging to the ATP-binding cassette (ABC) 
transporters sub-family. These proteins are widely expressed in many vital organs such as the 
brain, liver, lung and kidney, protecting them through the efflux of chemical and biological toxic 
substances. The broad substrate specificity of these efflux proteins leads to a severe reduction in 
the blood to organ penetration of chemotherapeutic agents (76-79).  
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Several investigators have reported the expression of P-gp and Mrp1 or Mrp2 on the ciliary 
epithelial cells in the BAB, and on the endothelial cells of the retinal blood vessels and the RPE in 
the BRB, in humans and in various animal models (80-84). However, the specific impact of P-
gp/Mrp1 in the blood-organ penetration of lipophilic drugs remains uncertain due to the presence 
of multiple influx and efflux transporters in the blood-organ membrane barriers (80,85). The co-
existence of several influx transporters, like organic cation/carnitine transporters (Oct), organic 
anionic transporters (Oat), organic anionic transporter polypeptides (Oatp) and multidrug 
resistance associated efflux proteins in the BOB confounds delineation of the contribution of P-gp 
and Mrp1 in hindering the blood-ocular transport of drugs (85-87).  
The application of multidrug resistance Mdr1a gene, responsible for P-gp expression, and 
Mrp1 gene knock-out (KO) mice, and recently rat, models have gained importance in delineating 
the P-gp and/or Mrp1 mediated efflux, and its effect on pharmacokinetics of substrates drugs 
(88,89). Numerous reports have discussed the use of transgenic mice models lacking the Mdr1a 
gene (P-gp KO) or Mrp1 gene as a powerful tool in unlocking the complexity and the role of efflux 
proteins on the penetration of anticancer drugs across the blood brain barrier (BBB) (88,89). The 
utilization of Mdr1a gene and Mrp1 gene KO mice and/or rats, to determine the impact of efflux 
proteins in the BOB, however, has remained largely unexplored. 
Several investigations reported the possibility of inhibiting P-gp and Mrp1 activity to 
enhance penetration of substrate molecules into the target organs (90,91). Drugs like verapamil, 
quinidine, cyclosporine etc., emerged as the first-generation P-gp inhibitors, modulating efflux 
activity at the blood-organ interface (92,93). Nonetheless, the toxic and antagonistic effects 
associated with their pharmacological activity and their ability to modulate the kinetics of substrate 
drugs, limited their use as specific inhibitors (94,95). Interestingly, the second-generation P-gp 
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inhibitors with diminished pharmacological activities were more potent and compatible in 
reducing the barrier characteristics (90,95,96). The third-generation P-gp inhibitors, like elacridar 
(EQ) and tariquidar (TQ), were developed with no pharmacological activity and with higher 
affinity to P-gp (at nanomolar concentrations) (90,97,98). EQ and TQ alleviate breast cancer 
resistance protein (BCRP) mediated efflux transport of the substrate molecules (97,98). Both EQ 
and TQ have been extensively explored for modulating the P-gp transporter at the blood brain 
barrier (BBB) thereby, improving the blood to brain penetration of substrate anticancer molecules 
(76,97-99). Similarly, MK 571 (MK) and probenecid (PB) were exclusively investigated as potent 
Mrp1 inhibitors (100,101). Beside modulating the Mrp1 activity, PB also inhibits the activity of 
several other transporters such as Mrp 2-5, Oat, Oct, Oatp etc. (102). 
Inhibition of P-gp, but not Mrp1 efflux protein, in the BOB has been studied by several 
investigators. The effect of either EQ or TQ on the BRB has been investigated on humans, rabbits 
and in vitro cell models, but not in rats (103-105). Previously, the contribution of topically 
administered first-generation P-gp inhibitors in improving the blood-ocular penetration of 
systemically and intravitreally administered substrates has been successfully investigated in New 
Zealand albino rabbits (106,107). However, the effectiveness of the third-generation P-gp 
inhibitors (EQ and TQ) and Mrp1 inhibitors (MK and PR) in regulating the activity of the 
respective efflux proteins in the BOB in Sprague-Dawley (SD) rats, has not been investigated till 
date. 
In view of this, the current study, for the first time, aimed to examine 1) the impact of P-
gp and Mrp1 barrier properties by comparing the transport of substrate anticancer drugs, paclitaxel 
(PTX) and methotrexate (MTX), across the BOB of Mdr1a and Mrp1 KO and wild type (WT) rats 
and, 2) the impact of third-generation P-gp inhibitors and Mrp1 inhibitors on the blood-ocular 
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transport of these substrate anticancer drugs. Earlier literature reports demonstrated that the blood-
brain transport of PTX was restricted by P-gp and that the transmembrane penetration of MTX 
was influenced by Mrp1 activity (88,89,108).  Hence, these substrate anticancer drugs were 
selected for the present study. Electroretinography (ERG) studies were undertaken to evaluate the 
effect of the substrate/inhibitors on the functional activity of the retinal cells. 
3.2. Materials and Methods 
3.2.1. Animals. 
Six to eight-week-old male WT, Mdr1a gene KO and Mrp1 gene KO Sprague-Dawley (SD) rats 
were purchased from Horizon Discovery (Saint Louis, MO). The animals had free access to food 
and water. All animal experiments were performed according to the approved protocols of the 
University of Mississippi Institutional Animal Care and Use committee, the University of 
Tennessee Health Science Center Institutional Animal Care and Use committee and the 
Association for Research in Vision and Ophthalmology statement for the Use of Animals in 
Ophthalmic and Vision Research. 
3.2.2. Chemical Reagents 
PTX, MTX, Cremophor EL ® and glycofurol was procured from Sigma Aldrich (St. Louis, MO). 
EQ, TQ, MK and PR were acquired from Alfa Aesar (Haverhill, MA). Propylene glycol (PG) (1,2-
Propanediol), Polyethylene glycol 400 (PEG-400), Polyethylene glycol 300 (PEG-300), Dimethyl 
Sulfoxide (DMSO) were purchased from Fisher Scientiﬁc (St. Louis, MO). All other high purity 
chemicals and HPLC grade solvents were also obtained from Fisher Scientific (St. Louis, MO).   
3.2.3. P-gp protein expression by western blotting 
Western blot was performed to understand the expression of P-gp in the BAB and BRB of the WT 
and P-gp KO SD rats. The WT and P-gp KO rats were euthanized by injecting an excess dose of 
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ketamine and xylazine combination through the I.P. route (n=6). The eyes were enucleated 
immediately and the ocular tissue (IC and RC) samples were collected. The tissues were harvested, 
and tissue lysates were prepared using 2X lysis buffer (Cell Signaling Technology, USA). Protein 
concentrations in the tissue lysates were estimated by Bradford assay (Bio-Rad USA). Equal 
amounts (20 µg) of proteins, from the various tissue lysates, were loaded into the wells of 10% 
SDS-PAGE mini-gels (Bio-Rad, USA), electrophoresed and the proteins were then transferred to 
nylon membranes (Cell Signaling Technology, USA) as per the western blot protocol.  Membranes 
were then blocked in 5% non-fat dried milk in 1X TBST [20 mM Tris–HCl (pH 7.5), 137 mM 
NaCl and 0.1% (v ⁄ v) Tween 20] for 1h at room temperature. Blots were probed overnight with 
primary antibody MDR1/ABCB1 (Cat # 13978 Cell Signaling Technology) following the 
manufacturers protocol. The membranes were washed with 1X TBST and probed with anti-rabbit 
secondary antibody conjugated to HRP (Cat # 7074 Cell Signaling Technology) for 1 hr. For equal 
loading, samples were probed with beta actin antibody (Cell Signaling Technology, USA). The 
blots were developed with signal flame enhanced chemiluminescence (ECL) TM kit (Cell 
Signaling Technology, USA). The images were captured, processed and analyzed on 
ChemiDoCTM MP imaging system (Bio-Rad, USA). ImageJ was used to compute the area of the 
protein band in the blot. Further, relative P-gp protein intensity was calculated from the ratio of P-
gp band area and the corresponding β-actin band area. 
3.2.4. Preparation and evaluation of substrate and inhibitor intravenous solutions 
PTX intravenous solution (3 mg/mL) was prepared by dissolving an appropriate quantity in a 
mixture of ethanol (30 %v/v) and cremophor EL (30 % v/v) and final volume was adjusted with 
saline (40 % v/v). MTX solution (8 mg/mL) was obtained by dissolving accurately weighed 
amount drug in 0.1N NAOH (20 % v/v), pH adjusted to 7.0 with 0.1N HCl (5 % v/v) and final 
46 
 
volume was made up with water for injection (75 % v/v). EQ solution (10 mg/mL), for intravenous 
administration, was obtained by dissolving an accurately weighed amount of EQ in DMSO (5 % 
v/v) and then the final volume was made up with glycofurol (5% v/v), PEG 300 (20% v/v), ethanol 
(30% v/v) and saline (40 % v/v). A clear solution of 2.5 mg/mL of TQ was prepared by dissolving 
an accurately weighed quantity of TQ in DMSO (5% v/v), glycofurol (10% v/v) PEG 400 (30% 
v/v), propylene glycol (25% v/v), and the required volume adjusted by the addition of saline. 2.5 
mg/mL of MK intravenous solution was prepared by dissolving accurately weighed amount in 
DMSO (5 % v/v), glycofurol (10% v/v), ethanol (20 % v/v), PG (30 % v/v) and final volume was 
made up with saline (35 % v/v). PB intravenous solution (25 mg/mL) was formulated by dissolving 
appropriate amount of PB in DMSO (5 % v/v), 1N NAOH (20% v/v), ethanol (10 % v/v), PG (25 
% v/v) and saline (40% v/v) was added to make up to the required volume. All these intravenous 
solutions were tested for pH, assay, precipitation in phosphate buffered saline (pH 7.4), stability 
at room temperature and for loss during filtration across 0.22µm nylon filter (Millipore, USA). 
3.2.5. Electroretinography 
The evaluation of substrate (PTX or MTX) or inhibitor (EQ/TQ/MK/PR) incompatibility with the 
retinal tissues was investigated by employing electroretinography (ERG) recordings. The analysis 
was performed on WT (n=33), P-gp KO (n=12) and Mrp1 KO (n=6) SD rats from the same cohort 
utilized in ocular distribution studies, as per the standard protocols. 
Substrates only: WT and P-gp KO rats, 12 of each, were intravenously administered 1 mg/kg or 3 
mg/kg of PTX and the ERG recording was collected before administration as well as at the end of 
2h and 24h (n=3 of each WT and P-gp KO rats/dose/time point) post-drug administration. Three 
of each WT and Mrp1 KO rats were administered 8 mg/kg of MTX while another three of each 
WT and Mrp1 KO rats were administered 4 mg/kg of MTX. The ERG recording was collected 
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before the administration of MTX as well as at the end of 2 h, post-drug administration. Since, 
significant changes in ERG patterns were noticed at end of 2h post 8 mg/kg dose treatment, 
suggesting the retinal toxicity, no ERG measurements were recorded for 24h.     
Inhibitors only: Fifteen WT rats were divided into 5 groups with 3 rats in each group (n=3). Each 
study group received only one treatment of intravenous EQ (15 mg/kg) or TQ (15 mg/kg) or TQ 
(5 mg/kg) or MK (5 mg/kg) or PR (25 mg/kg). The ERG recordings were measured before and 2h 
after inhibitor administration.  
 Briefly, dark-adapted rats (overnight prior to commencement) were anesthetized with an 
I.P. injection of ketamine and xylazine combination. Gold ring electrodes of 2-3 mm diameter 
(Roland Consult, Stasche & Finger GmbH), were positioned on both corneas after anesthetizing 
them with topical 0.5% proparacaine hydrochloride followed by topical application of 1% 
tropicamide for pupil dilation. The stainless-steel surgical needles were inserted subcutaneously 
into the forehead and back leg to serve as reference and ground electrodes respectively. The dark-
adapted ERG responses were recorded from both the eyes simultaneously, exposing them to 
flashes of various intensities (from −4.0 Log units to 2.88 Log units) delivered by a Ganzfeld light 
source. The amplitudes of a- wave (relevant to photoreceptor functioning by light accommodation) 
and b-wave (relevant to bipolar and/or Müller cell functioning) of WT, P-gp KO and Mrp1KO rats 
obtained before dosing were considered as baseline to compare and find the differences in the 
amplitudes of a- and b- waves recorded by the end of 2 h and/or 1 day after dosing. The deviations 
in the intensities of the amplitudes were reported as percentage changes of amplitude. 
3.2.6. Ocular distribution 
The first objective was to estimate the impact of P-gp and Mrp1 on the ocular penetration of PTX 
and MTX, respectively. Ocular distribution studies were thus undertaken in WT, P-gp KO and 
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Mrp1 KO rats. Since there was no indication in the literature that the expression of the transporters 
on the ocular tissues was gender dependent, male SD rats only were selected for the study. A total 
of 96 rats were used in these studies (48 WT, 24 P-gp KO, and 24 Mrp1 KO). Twelve of the WT 
and 12 of the P-gp KO rats were administered 1 mg/kg PTX, while the other 24 (12 WT and 12 P-
gp KO) were injected 3 mg/kg dose, through the tail vein. Similarly, twelve of each WT and Mrp1 
KO rats were administered 4 mg/kg MTX, while the other 24 (12 WT and 12 Mrp1 KO) were 
injected 8 mg/kg dose, through the tail vein. At the end of 60 and 120 min, post dosing, WT and 
P-gp KO or Mrp1 KO rats from each group (n=6 at each time point) were anesthetized with an 
intraperitoneal (I.P.) administration of a combination of ketamine (35 mg/kg) and xylazine (3.5 
mg/kg). Blood was collected via cardiac puncture. The animals were then euthanized using an 
excess combination dose of ketamine and xylazine through the I.P. route and the eyes were 
enucleated immediately. Aqueous humor (AH) and vitreous humor (VH) were collected from both 
eyes of each rat and was pooled. The blood samples collected were immediately centrifuged at 
10,000 rpm for 5 min and the plasma was separated. Plasma, AH and VH samples were stored at 
-80 OC until analysis. 
 The second objective was to estimate the ability of P-gp inhibitors (EQ and TQ) and Mrp1 
inhibitors (MK and PR) to modify the P-gp and Mrp1 activity in the BOB, as evidenced by changes 
in the blood-ocular penetration of PTX and MTX. Ocular distribution studies were carried out in 
WT SD rats. The rats were placed in 12 treatment groups (n=6), so that each group receive only 
one treatment: PTX (1 mg/kg) + EQ (5 mg/kg); PTX (1 mg/kg) + EQ (15 mg/kg); PTX (1 mg/kg) 
+ TQ (2.5 mg/kg); PTX (1 mg/kg) + TQ (5 mg/kg); PTX (3 mg/kg) + EQ (5 mg/kg); PTX (3 
mg/kg) + EQ (15 mg/kg); PTX (3 mg/kg) + TQ (2.5 mg/kg); PTX (3 mg/kg) + TQ (5 mg/kg); 
MTX (4 mg/kg) + MK (2.5 mg/kg); MTX (4 mg/kg) + MK (5 mg/kg); MTX (4 mg/kg) + PR (15 
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mg/kg); and MTX (4 mg/kg) + PR (25 mg/kg), through the tail vein. Animals were injected with 
P-gp (EQ or TQ) or Mrp 1 inhibitor (MK or PR) 30 min prior to the PTX or MTX administration. 
At the end of 60 min post PTX or MTX dosing, the rats were anesthetized by an intraperitoneal 
(I.P.) administration of a combination of ketamine (35 mg/kg) and xylazine (3.5 mg/kg) and the 
blood was collected via cardiac puncture. The animals were then euthanized with an excess dose 
of ketamine and xylazine combination injection through the I.P. route. Immediately after 
euthanization, the eyes were enucleated. Aqueous humor (AH) and vitreous humor (VH) were 
collected from both eyes and pooled. The blood samples were processed similarly as mentioned 
earlier and plasma was collected. All these tissue samples were kept at -80 oC until further analysis 
were performed. 
3.2.7. Sample Preparation 
To 80 µL plasma, 20 µL AH and 40 µL VH tissue samples, 10 µL, 2.5 µL, and 5 µL, respectively, 
of 1 µg/mL docetaxel (DTX) (internal standard for PTX(IS)) or 0.5 µg/mL of phenacetin (IS for 
MTX) solution was added. Then ice-cold acetonitrile (2 parts) was added to the samples (1 part) 
to extract drug and internal standard from the biological matrices with complete precipitation of 
proteins. Furthermore, the samples were vortexed and then centrifuged at 13000 rpm for 15 min 
and the clear supernatant solution was collected. The eluents in the supernatant solution (2 μL) 
were quantified using the following LC/MS method. The extraction efficiency (EE), limit of 
detection (LOD) and linearity in plasma (10-100 ng/mL), AH (0.5-40 ng/mL) and VH (0.5-20 
ng/mL) was assessed. 
3.2.8. Quantification of PTX and MTX  
The quantity of PTX and MTX in the plasma, the AH and the VH samples were determined with 
the ACQUITY UPLC® I-Class System (Waters Corporation, Milford, MA, USA) connected to 
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Waters Xevo TQ-S triple quadrupole tandem mass spectrometer with an electrospray ionization 
(ESI). Data acquisition and processing were controlled by Waters Xevo TQ-S quantitative analysis 
TargetLynx software and MassLynx mass spectrometry software, respectively. Separation of PTX 
was achieved on an Acquity UPLCTM Cortecs C18 (2.1x100 mm; 2.7 µm) column with operations 
were accomplished using a C18 column (Acquity UPLC® BEH C18 100 mm×2.1 m, 1.7µm 
particle size). The mobile phase comprised of water (A) and acetonitrile (B), both containing 0.1 
% formic acid, at a flow rate of 0.7 mL/min, which were applied in the following gradient elution: 
0 min,55 % A: 45% B, in next 2.5 min to 50% B, and next 0.2 min; to 100 % B, and then to 55% 
A for next 2.5 min. Each run was followed by a 3 min wash with 100 % acetonitrile, and an 
equilibration period of 1 min. The column temperature was set at 50 °C. Two microliters of sample 
was injected into the column and the effluent was directed into the ESI probe (source) operated 
using following parameters: source temperature 60°C, desolvation temperature 600°C, capillary 
voltage 2.0 kV, cone voltage 30 V, nebulizer pressure-7 bar, desolvation gas flow 1200 L/h N2 and 
cone gas flow 150 L/h N2. The collision energies ranging from 20 to 64 eV were optimized, for 
individual analytes. Argon served as the collision gas. All the instrument operations were 
controlled by MassLynx software (version 4.1, Waters, Milford, MA, USA). Mass spectra of each 
sample was acquired in positive mode. The precursor to daughter ions transitions (quantifier ion 
to qualifier ions transitions) of PTX (m/z 854.31 → m/z 286.14, 122.08, 195.06) and docetaxel 
(DTX) (m/z 808.37 → m/z 527.23, 327.15, 105.06) was monitored in multiple reaction monitoring 
(MRM) mode. The compounds were confirmed in each spectrum by the three daughter ions, each 
for PTX and DTX. 
 Similarly, the MTX was also analyzed using the same LC/MS system, column mobile 
phase, at a flow rate 0.8 mL/min, with slight changes in gradient elution as following; till 0.2 min, 
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98 % A: 2% B, in next 2.5 min to 100% B and maintain for 1 min then to 98% A:2% B, in next 1 
min. Each run was followed by a 1 min wash with 100 % acetonitrile, and an equilibration period 
of 3 min. The column and sample temperatures were set at 50 °C and 10 °C, respectively. Two 
microliters of sample was injected into the column and the effluent was directed into the ESI probe 
(source) operated using following parameters: source temperature 60°C, desolvation temperature 
600°C, capillary voltage 2.0 kV, cone voltage 10 V, nebulizer pressure-7 bar, desolvation gas flow 
1200 L/h N2 and cone gas flow 200 L/h N2. The collision energies ranging from 18 to 34 eV were 
optimized, for individual analytes. Mass spectra of each sample was acquired in positive mode. 
The precursor to daughter ions transitions (quantifier ion to qualifier ions transitions) of MTX (m/z 
455.08 → m/z 308.16, 175.08, 134.08) and phenacetin (PH) (m/z 180.06 → m/z 110.06, 92.90, 
65.08) was monitored in multiple reaction monitoring (MRM) mode. The compounds were 
confirmed in each spectrum by the three daughter ions, each for MTX and PH. 
3.2.9. Data Interpretation  
The variations in the plasma concentration of substrate drug (PTX or MTX) could be attributed to 
the differences in their AH and the VH levels, which could confound the impact of P-gp or Mrp1 
on the permeation process. Hence, ocular tissue-to-plasma ratio of substrate drug concentration is 
a more important parameter to determine the impact of P-gp or Mrp1 activity and inhibition in the 
BOB. 
 Thus, drug (PTX or MTX) distribution into the AH and VH from plasma was calculated 
according to equations 1 & 2 respectively, 
012  +3456%673	38	9:;	3	<:;	7	=>	?/@A+3456%673	38	9:;	3	<:;		7	9(%@%	?/@A                      (Eq. 1) 
0B2  +3456%673	38	9:;	3	<:;		7	C>	?/@A+3456%673	38	9:;	3	<:;		7	9(%@%	?/@A                      (Eq. 2) 
52 
 
Where, DAH and DVH represents the distribution ratios delineating the penetration of PTX or MTX 
from plasma into AH and VH, respectively. 
3.2.10. Statistical analysis  
The data obtained from ocular distribution and ERG studies were subjected to one-way analysis 
of variance (ANOVA) and Tukey’s post hoc HSD (GraphPad Software, San Diego California, 
USA), to estimate the statistical signiﬁcance. The p < 0.05 were considered statistically significant.  
3.3. Results and discussions 
All intravenous solutions were clear with pH of 6.7 -7.0 and showed an assay of 94.8-103.0% 
(Table 3.1). No significant loss of drug (< 1 %) was noted during filter validation (passing these 
solutions through 0.22 µm nylon filter). Moreover, no precipitation was seen after introducing 
these solutions into phosphate buffer saline (pH 7.4), ruling out the possibility of precipitation at 
the injection site (Table 3.1).  
 
 
 
 
 
 
 
Table 3.1:  Evaluation of formulations containing P-gp and Mrp1 substrates and 
inhibitors. 
Evaluation 
parameters 
Formulations 
PTX EQ TQ MTX PB MK 
% Assay 102.31 103.03 97.88 101.31 95.49 94.80 
pH 6.7 6.7-6.8 6.7-6.8 6.8-7 6.8-7 6.8 
Loss on 
Filtration 
(%) 
0.34 0.44 0.36 0.43 0.51 0.53 
Appearance Clear Clear Clear Clear Clear Clear 
On-site 
precipitation 
No No No No No No 
Stability @ 
RT 
30 days 30 days 7 days 30 days 7 days 7 days 
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All these formulations were stored at room temperature for 1-4 weeks and were found to be stable 
with ≤ 2% change in the assay during this period (Table 3.1). These intravenous solutions were 
prepared as mentioned in earlier literature reports, with slight modifications (103-105,108). The 
excipient concentrations utilized in the formulations were within the limits noted in the inactive 
ingredients (IIG) database of US Food and Drug Administration (US-FDA) and/or below reported 
intravenous LD50 values in rats, to ensure safety and biocompatibility of these parenteral solutions 
(109,110).    
The LC/MS method adopted for the analysis of PTX and MTX was sensitive with a limit of 
detection (LOD) of 0.1 ng/mL, and a limit of quantitation (LOQ) of 0.5 ng/mL in the ocular tissues 
and was linear over the range of concentrations tested with r2 values of 0.993, 0.990 and 0.994 in 
plasma, AH and VH, respectively. >85 % of PTX and ~92 % of MTX were extracted from all 
tissues by protein precipitation technique using ice cold acetonitrile. The bioanalytical method was 
 
Fig. 3.1: A) Western-blot displaying the P-gp protein and β-actin bands in the IC and RC samples obtained from 
WT and P-gp KO SD rats. B) The relative P-gp protein intensity was determined from the ratio of area obtained 
from P-gp protein band and β-actin band using ImageJ. 
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specific to PTX and/or MTX, specific IS’s as well, without any interference. The % recovery of 
these substrate drugs from the samples stored at 40 OC and freshly obtained samples were 93.3 % 
and 91.3%, respectively, suggesting low or no drug loss during the storage of the samples. 
3.3.1. P-gp protein expression in ocular tissues 
Literature reports describe the utility of the western blotting, reverse transcription-polymerase 
chain reaction (RT-PCR) and immunohistochemistry techniques in determining the P-gp protein 
expression in the ocular tissues (111). In the current study, the western blot results portrayed a 
protein band with MW ~170 kDa in the IC and RC samples obtained from the WT, confirming the 
existence of the P-gp protein in the BAB and the BRB, respectively (Fig. 3.1A). The higher relative 
P-gp protein intensity in the IC compared to that in the RC demonstrated higher P-gp expression 
in the IC than in the RC, suggesting greater MDR 1a efflux activity in the BAB over that in the 
BRB (Fig. 3.1B). A few literature reports also demonstrated the variations in the P-gp mediated 
efflux of substrates at the BAB and the BRB, in rat models, confirming the differential expression 
of P-gp in the BAB and the BRB (112, 113). In contrast, no band at 170 kDa MW mark in the IC 
and RC tissues collected from P-gp KO rats confirmed the absence of P-gp expression in their 
BAB and the BRB. Thus, these results suggest the applicability of P-gp KO rats as a suitable model 
to delineate impact of P-gp mediated efflux of anticancer drugs in the BOB.   
3.3.2. Electroretinography 
Electroretinography (ERG) was performed to understand substrate-inhibitors interactions with the 
retina thereby affecting the functioning of photoreceptors cells and inner retinal cells. The ERG 
measures the functioning of photoreceptor cells and bipolar/Müller cells as a-wave and b-wave, 
respectively. Changes in the a-wave recording suggest light or chemical induced alterations in the 
functioning of photoreceptors cells in the outer segment of the retina, while the variations in the 
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b-wave recordings suggest damage to the inner retina (114-116). Hence, the % change in the 
amplitude of a- and b-wave were examined to understand the cytocompatibility of substrate and/or 
inhibitor interactions with retina of WT, P-gp KO and Mrp1 KO SD rats. 
 The percentage changes of a- and b- wave amplitudes obtained from the ERG studies in WT and 
P-gp KO rats, pre- and post-dosing of PTX (two doses), is presented in Figure 3.2A. The a-wave 
amplitude in P-gp KO rats, 2h and 1day post treatment with 3 mg/kg of PTX, changed significantly 
with respect to baseline (p<0.05) (Fig. 3.2A). Similarly, at 1day post treatment with 3 mg/kg PTX, 
the b-wave amplitude, in P-gp KO rats, changed significantly from the baseline suggesting the 
Fig. 3.2: Electroretinography results depicting the % change from the baseline in the amplitude of a- and b-
wave recorded A) at 2h and 1day post PTX (two doses) in WT and P-gp KO rats, and B) at 2h post 
administration with MTX (two doses) in WT and Mrp1 KO rats, and C) at 2h post P-gp (EQ and TQ) or Mrp1 
inhibitor (MK and PR) in WT rats (mean ± SEM, n=3). * - significantly different at p<0.05. 
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damage of inner retinal layer by PTX, at this dose (p<0.05) (Fig. 3.2A). These results verify several 
reports which demonstrated PTX induced retinal degeneration, at higher dose (3-6 mg/kg) 
(117,118). No change was observed in the a- and b-wave amplitude in both WT and P-gp KO rats 
administered with low dose (1 mg/kg) of PTX (Fig. 3.2A), confirming the lack of structural and 
functional alterations in the retina. 
 The WT rats treated with MTX high dose (8 mg/kg) showed a significant % change in the 
a-wave amplitude, from the baseline, 2h post treatment, but no change in the b- wave was noticed. 
The ERG wave pattern recorded in the Mrp1 KO rats, 2h post MTX treatment, were not different 
from the baseline recording. These results suggested that MTX at higher dose could cause a toxic 
interaction with retina (Fig. 3.2B). ERG recordings measured in WT and Mrp1 KO rats 
administered with low dose (4 mg/kg) of MTX were not statistically different from the baseline 
recording and suggested that MTX at low dose (4 mg/kg) is retina compatible (Fig. 3.2B). 
 All the inhibitors (EQ, TQ, MK and PR) were tested for their retinal compatibility, in WT 
rats, and, safe doses were selected for the ocular distribution studies. The % change in the 
amplitude of a- and b-wave recordings of all the inhibitors is given Figure 3.2C. Except for TQ 15 
mg/kg dose, all other inhibitors, at tested doses, did not show significant % change in the a and b 
wave amplitude with respect to the baseline suggesting retinal safety. However, TQ at 15 mg/kg 
showed significant % change in the b-wave amplitude from the baseline recording, at 2h post 
dosing, suggesting retinal toxicity at this dose. The lower TQ dose was observed to be safe. 
3.3.3. Ocular distribution 
The substrates and inhibitor doses tested in the present studies were selected from literature 
reports which demonstrated the impact of P-gp and Mrp1 activity and inhibition in the BBB of 
WT and/or P-gp or Mrp1 KO rats/mice (76,101-105,119,120).  
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3.3.3.1. Impact of P-gp activity and it’s inhibition on the blood-ocular penetration of 
PTX 
a. Plasma concentration of PTX 
PTX concentration determined in the plasma of rats from different treatment groups are 
represented in Figure 3.3. A dose related increase in the plasma PTX levels was observed in both 
WT and P-gp KO rats (Figure 3.3A). As the administered dose of PTX increased from 1 mg/kg to 
3 mg/kg, a ~3 – 4-fold increase in the plasma drug concentrations was observed in both WT and 
P-gp KO rats, at both the time points (p<0.05) (Fig. 3.3A). The plasma PTX concentration in the 
P-gp KO rats was significantly higher compared to the WT rats, at 60 min (both doses) and 120 
min (3 mg/kg dose alone) (p<0.05) (Fig. 3.3A). At 120 min post 1 mg/kg administration, the 
plasma PTX concentration in the P-gp KO rats were slightly higher over that observed in WT rats 
but were not statistically different (Fig. 3.3A). These results corroborate with previous reports 
which demonstrated a ~1.5-fold higher plasma PTX levels in the P-gp KO rats, compared to WT 
 
Figure 3.3: The plasma concentrations of PTX in the rats from different treatment groups. A) Plasma PTX levels 
in WT and P-gp KO rats, at 60 and 120 min post administration with 1 mg/kg or 3 mg/kg dose of PTX. B) Plasma 
PTX levels in the WT rats, at 60 min post co-administration with P-gp inhibitors (EQ or TQ) and PTX (1 mg/kg). 
α- indicates significant difference at p<0.05, between WT or P-gp KO 1 mg/kg vs WT or P-gp KO 3 mg/kg, at 
same time point; *-indicates significant difference at p<0.05, between WT vs P-gp KO, at same dose and time 
point (mean ± SEM, n=6). 
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(88). This is probably due to reduced renal clearance of PTX in the Mdr1a gene KO rats due to the 
lack of P-gp expression in the renal cells (88).  
 At 60 min post PTX (1 mg/kg) administration, the plasma PTX concentration observed in 
the WT rats pretreated with P-gp inhibitors (either EQ or TQ, at both doses) were slightly higher, 
but not statistically different, from that observed in the WT rats treated with PTX alone (Fig. 3.3B). 
This might be due to the partial or incomplete inhibition on P-gp activity, by EQ or TQ (at tested 
doses), leading to no significant change in the renal clearance of PTX. 
b. Blood-to-AH penetration of PTX  
To estimate the penetration of PTX into the AH from the systemic circulation, AH PTX and the 
AH to plasma distribution ratio of PTX (DAH), in P-gp KO rats and WT rats in different treatment 
groups, were estimated and are illustrated in Figure 3.4. 
 Dose related drug levels were noticed in the AH of WT and P-gp KO rats, at both doses 
and time points (Fig. 3.4A). At the lower dose (1 mg/kg), PTX concentrations were below LOD 
in the AH of the WT rats at both time-points (Fig. 3.4A). On the other hand, at the same dose, 
significant PTX levels were detected in the AH of P-gp KO rats, at the both time points, but, the 
concertation of PTX noted at120 min were below the LOQ (Fig. 3.4A). The penetration or 
distribution of PTX from blood into AH was determined as the AH to plasma drug concentration 
ratio (DAH). The DAH of PTX in WT rats treated with the low dose was zero for both the time-
points since no drug levels were detected in the AH. The DAH of PTX in the P-gp KO rats injected 
with low dose (1 mg/kg) was significantly better compared to that of the WT rats, at 60 min 
(p<0.05) (Fig. 3.4B). At the higher dose (3 mg/kg) treatment, the average concentrations of PTX 
in the AH obtained in the P-gp KO rats, at 60 min, were ~ 2-fold higher (p<0.05) than that of the 
WT rat (Fig. 3.4A). The DAH of PTX in P-gp KO rats were significantly higher than that seen in 
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WT rats, at 60 min. Hence at 60 min point, at both the doses, the influence of P-gp on the transport 
of PTX across the BAB was clearly evident (p<0.05) (Fig. 3.4A). These findings agree with 
previous reports on the expression of P-gp at BAB (3,81). At 120 min, no or low DAH in both WT 
and P-gp KO, compared to that observed at 60 min, suggests the elimination of drug from the 
blood and the AH, at both the doses of PTX.  
 Surprisingly, the DAH of PTX in P-gp KO rats administered with 1 mg/kg dose, at 60 min, 
was significantly higher than that observed in P-gp KO rats treated with 3 mg/kg dose (Fig. 3.4B). 
This could be possibly due to the damage to the BOB induced by PTX at 3mg/kg dose, as noticed 
in the ERG studies. Thus, 1 mg/kg PTX dose was selected to investigate the impact of the P-gp 
Fig. 3.4: The aqueous humor (AH) PTX levels (A & C) and AH to plasma distribution ratio of PTX (DAH) (B 
& D) in the P-gp KO rats and/or WT rats in different treatment groups. ND-Not detected; BQ- Below the 
LOQ; NC-Not calculated;* - indicates significant difference at p<0.05, between WT or P-gp KO 1 mg/kg vs 
WT or P-gp KO 3 mg/kg, at same time point or between WT rats pretreated with low dose of P-gp inhibitors 
(EQ or TQ) vs WT rats pretreated with high dose of P-gp inhibitors (EQ or TQ), at 1 mg/kg dose of PTX and 
60 min point; α -indicates significant difference at p<0.05, between WT vs P-gp KO, at same dose and time 
point; #-significantly different from WT rats treated with PTX (1 mg/kg) alone (p<0.05), ᴪ- significantly 
different from all (p<0.05) (mean ± SEM, n=6). 
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activity inhibition on the blood-AH penetration of PTX in the WT rats pretreated with third 
generation specific P-gp inhibitors, EQ and TQ.  
  In the presence of EQ or TQ (at both the doses), the penetration of PTX (1 mg/kg 
dose) into the AH from blood in the WT rats were significantly higher (p<0.05) compared to that 
in the WT rats not receiving the inhibitors (Fig. 3.4C). The AH levels and DAH of PTX in WT rats 
co-administered with P-gp inhibitors and PTX increased with an increase in the EQ or TQ dose 
(Fig 3.4C). A 2-fold improvement in the AH PTX levels and DAH of PTX were noticed in WT rats, 
pre-administered with high dose of EQ (15 mg/kg) or TQ (5 mg/kg), compared to that seen in the 
WT rats administered with low dose of EQ (5 mg/kg) or TQ (2.5 mg/kg) (Fig 3.4C and Fig. 3.4D). 
These results indicate enhanced plasma to AH penetration of PTX, suggesting effective 
modulation of P-gp in the BAB by the inhibitors (EQ or TQ). The above findings corroborate with 
the literature reports which demonstrate the interaction of EQ and TQ with the MDR 1a efflux 
transporter function. This modulation of P-gp efflux activity is due to blocking of the 
drug/substrate binding site by EQ or because of blocking of both drug binding and ATP binding 
sites by TQ, in the P-gp structure (97,122). The AH PTX levels and DAH of PTX in the WT rats 
administered with EQ, at low dose (5 mg/kg), were not statistically different from those noted in 
the rats pretreated with TQ, at low dose (2.5 mg/kg) (Fig 3.4C and Fig. 3.4D). Similarly, no 
statistically significant difference was found between the AH PTX levels and DAH of PTX in the 
WT rats treated with 15 mg/kg dose of EQ and WT rats injected with 5 mg/kg of TQ (Fig 3.4C 
and Fig. 3.4D). It has been reported that TQ (IC50 ≤ 0.05 µM) has greater affinity for P-gp 
compared to EQ (IC50 ≤ 0.1 µM) (97). Hence, even at 2-3-fold lower dose compared to EQ, TQ 
produced P-gp inhibitory effects similar to that of EQ and no statistical difference in AH PTX 
levels and DAH was noted (Fig 3.4C and Fig. 3.4D).  
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The above results confirm that P-gp on the BAB restricts penetration of PTX into the AH from the 
blood and that effective inhibition of this P-gp activity improves the penetration of PTX across the 
BAB into the AH. 
c. Blood-to-VH penetration of PTX  
 Dose related VH PTX levels were observed in both WT and P-gp KO rats (Fig. 3.5A). In the VH 
of WT rats, at 1 mg/kg dose, PTX concentrations were below LOD at both time-points whereas, 
significant PTX levels were detected in the VH of P-gp KO rats at the 60-min time-point  (Fig. 
3.5B). Hence, the plasma to VH PTX distribution ratio (DVH) in P-gp KO rats receiving the lower 
dose, at 60 min, was significantly higher compared to that of the WT rats (p<0.05) (Fig. 3.5B). 
Fig. 3.5: The vitreous humor (VH) PTX levels (A & C) and VH to plasma distribution ratio of PTX (DVH) (B & D) 
in the P-gp KO rats and/or WT rats in different treatment groups. ND-Not detected; NC-Not calculated; BQ- below 
the LOQ; * - indicates significant difference at p<0.05, between WT or P-gp KO 1 mg/kg vs WT or P-gp KO 3 
mg/kg, at same time point or between WT rats pretreated with low dose of P-gp inhibitors (EQ or TQ) vs WT rats 
pretreated with high dose of P-gp inhibitors (EQ or TQ), at 1 mg/kg dose of PTX and 60 min point; α -indicates 
significant difference at p<0.05, between WT vs P-gp KO, at same dose and time point; #-significantly different 
from WT rats treated with PTX (1 mg/kg) alone (p<0.05) (mean ± SEM, n=6). 
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This demonstrates the superior penetration of PTX from blood to VH through the BRB of subjects 
lacking P-gp. Moreover, no PTX levels in the VH of WT rats suggests the influence of P-gp, at 
the blood-VH interface, on the penetration of PTX across the BRB. These results are in agreement 
with the previous literature reports on the barrier properties of P-gp in the BRB (3,4,80). With the 
3 mg/kg dose treatment, the VH PTX concentrations in the WT and P-gp KO rats, were not 
statistically different from each other, at any time point. Thus, the DVH of drug in WT and P-gp 
KO rats did not show significant difference at both time intervals post 3 mg/kg treatment (Fig. 
3.5B). This could be attributed to the retina structural damage induced by PTX, at 3 mg/kg dose, 
which was apparent from the ERG studies. Moreover, numerous investigations have reported that 
PTX, at high doses (3-6 mg/kg), induce retina degeneration in humans and SD rats (117,118). 
Hence, the 1 mg/kg dose and the 60 min time point were selected to investigate the impact of 
modulation of P-gp activity, by EQ or TQ, on the penetration of PTX across the BRB.  
 The WT rats co-administered with high dose of EQ (15 mg/kg) or TQ (5 mg/kg) and PTX 
(1 mg/kg) showed greater VH PTX levels over that seen in the WT rats administered with PTX 
alone (p<0.05) (Fig. 3.5C). Hence, the VH to plasma PTX distribution ratio (DVH) in WT rats 
receiving high dose of EQ and/or TQ were significantly higher compared to that of the WT rats 
receiving PTX alone (p<0.05) (Fig. 3.5D). As seen in blood-to-AH penetration of PTX, the VH 
levels and DVH of PTX in rats administered with higher dose of EQ or TQ were significantly higher 
than that of the rats administered with lower dose of inhibitors, and thus, suggested a dose related 
inhibition of P-gp activity (p<0.05) (Fig. 3.5C & Fig. 3.5D). However, at low dose of P-gp 
inhibitors, no PTX levels were detected in the VH of rats treated with TQ while the WT rats treated 
with EQ showed VH PTX levels, which were below the LOQ (Fig. 3.5C). This could be attributed 
to the partial or no inhibition of P-gp activity in the BRB by the EQ and TQ at low doses. These 
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results demonstrated effective modulation of P-gp activity in the BRB by EQ and TQ and agreed 
with the previous literature reports that demonstrate improved penetration of substrates across the 
BRB on modulating P-gp activity (80,105).  
3.3.3.2. Impact of Mrp1 activity and inhibition on the blood-ocular penetration of 
MTX 
a. Plasma Concentration of MTX 
Figure 3.6 delineates the plasma MTX concentrations in the WT rats and Mrp1 KO rats. 
The plasma concentration of MTX in both WT and Mrp1 KO rats was increased by ~ 2 - 3.5-folds 
with an increase in the administered MTX dose from 4 mg/kg to 8 mg/kg (Fig. 3.6A). At same 
dose and time point, the plasma MTX levels in the WT rats were about 1.2-3-fold higher compared 
to that seen in Mrp1 KO rats (Fig. 3.6A). Mrp1 efflux protein, situated on the basal side of the 
renal proximal tubular cells, promotes the renal reuptake of substrate drugs (102,123). Thus, the 
reduced reuptake of MTX in the Mrp1 KO rats resulted in lower plasma concentrations, compared 
to WT rats (Fig. 3.6A). The WT rats in the inhibitor treatment group also showed variations in the 
plasma MTX levels. At 60 min post-treatment with MTX in the WT rats pretreated with MK (at 
any given dose), the plasma concentration of MTX was not statistically different from that 
observed in the WT rats injected with MTX alone (4 mg/kg) (Fig. 3.6B). This could be attributed 
to the low levels of MK in the renal tubules resulting in no or partial inhibition of Mrp1 activity in 
the kidney and, thus, lead to MTX reuptake. The WT rats pre-administered with PR (at both doses) 
showed about 1.5 - 2.2-folds higher plasma concentration of MTX compared to that seen in WT 
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rats in any other group and Mrp1 KO rats injected with 4 mg/kg MTX (Fig. 3.6). This remarkable 
difference in the plasma MTX levels seen in WT rats pretreated with PR (at both doses) could be 
attributed to the effectiveness of PR in inhibiting a wide range of Mrp’s, Oat’s, Oatp’s etc (p<0.05) 
(102). These results support the previous literature reports which demonstrated PR as a potent 
inhibitor of Mrp2, Oat1 and Oat3 transporters, besides Mrp1, situated on the apical cells of 
proximal renal tubule and involved in the renal clearance of substrate drugs (102). Hence, the 
inhibition of Oat1, Oat3 and Mrp2, by PR, in the kidney resulted in decreased renal clearance of 
MTX and thereby increased plasma MTX levels in the WT rats. 
 
 
Fig. 3.6: The plasma MTX levels A) WT and Mrp1 KO rats treated with 4 mg/kg or 8 mg/kg, at 60 and 120 min, 
and B) WT rats co-administered with different doses Mrp1 or PB and MTX. of in different treatment groups. σ - 
indicates significant difference at p<0.05, between WT or Mrp1 KO 8 mg/kg vs WT or Mrp1 KO 4 mg/kg, at same 
time point; φ- indicates significant difference at p<0.05, between WT vs Mrp1 KO, at same dose and time point; 
∆- indicates significant difference at p<0.05, between MTX (4 mg/kg) and PB (25 mg/kg or15 mg/kg) vs MTX (4 
mg/kg) and MK (2.5 mg/kg or 5 mg/kg), WT (4 mg/kg) at 60 min and Mrp1 KO (4 mg/kg), at 60 min  (mean ± 
SEM, n=6). 
65 
 
b. Blood-to-AH penetration of MTX 
The AH levels and DAH of MTX in WT rats and Mrp1 KO rats, in different treatment groups, are 
presented in Figure 3.7. The MTX levels in the AH of WT and Mrp1 KO rats increased, 
corresponding to the dose administered, at 60 min (both at 4 mg/kg and 8 mg/kg dose) and 120 
min (only at 8 mg/kg) (Fig. 3.7A). At the 4 mg/kg dose, the AH MTX levels and the DAH of MTX 
in Mrp1 KO rats were about 2-fold higher (p<0.05) compared to that in the WT rats, at the 60 min 
time point (Fig. 3.7A and Fig. 3.7B). This suggests Mrp1 mediated efflux activity in the BAB, 
consistent with the literature reports that demonstrate Mrp1 expression in the apical membrane of 
Fig. 3.7: The aqueous humor (AH) MTX levels (A & C) and AH to plasma distribution ratio of MTX (DAH) (B & 
D) in the Mrp1 KO rats and/or WT rats in different treatment groups. * - indicates significant difference at p<0.05, 
between WT or Mrp1 KO 8 mg/kg vs WT or Mrp1 KO 4 mg/kg, at same time point; σ-significantly different from 
WT (4 m/kg MTX), at 60 min (p<0.05); Ф -significantly different from Mrp1 KO rats treated with MTX alone, at 
60 min (4 mg/kg) (p<0.05;α- indicates significant difference at p<0.05, between WT rats co-administered with 
MTX and MK or PB (high dose) vs WT rats co-administered with MTX and MK or PB (low dose); #-significantly 
different from WT rats treated with MTX (4 mg/kg) alone, at 60 min (p<0.05), ᴪ - significantly different from all 
(p<0.05) (mean ± SEM, n=6). 
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the non-pigmented ciliary epithelial cells (124, 125). Hence, in the absence of Mrp1 efflux protein 
expression in the KO rats, the AH MTX levels were higher compared to that noted in WT rats, at 
60 min post 4 mg/kg dose treatment.  At 8 mg/kg dose, the AH concentrations of MTX in WT rats, 
at both time points, were not significantly different from that observed in the Mrp1 KO rats which 
could be due to the damage to BOB, as seen in the ERG studies (Fig. 3.2C). Thus, the DAH of MTX 
estimated in the WT and Mrp1 KO rats, at both time points in 8 mg/kg dose study, were not 
statistically different (Fig. 3.7B). The AH MTX levels and the DAH of MTX in WT and Mrp1 KO 
rats, at 120 min, was about 2-4-fold lower compared to that noted at 60 min, at same administered 
dose, which might be possibly due to the clearance of MTX from plasma and AH. However, at 60 
min post 4 mg/kg dose treatment, the higher MTX concentrations in the AH and DAH of MTX in 
Mrp1 KO rats, over the WT rats, confirmed the active Mrp1 mediate efflux of the MTX across the 
BAB. Hence, this dose and time point was selected to understand the role of the Mrp1 inhibition 
on the penetration of MTX across the BAB. 
 The AH levels and the DAH of MTX estimated in the WT rats co-administered with MTX 
(4 mg/kg) and MK (5 mg/kg or 2.5 mg/kg) and/or PR (15 mg/kg or 25 mg/kg) were significantly 
higher compared to that seen in WT rats receiving MTX alone (Fig. 3.7C and Fig. 3.7D). This 
confirmed effective modulation of Mrp1 activity in the BAB and thereby, improved penetration of 
MTX into AH from blood. As the administered dose of the MK or PR ~ doubled, the AH MTX 
levels and DAH in the WT rats increased by about 1.5-2.0-fold and 1.2-1.7-fold, respectively, and 
suggested an inhibitor dose related modulation of Mrp1 activity at the BAB (Fig. 3.7C). 
Penetration of MTX into the AH (DAH) from the systemic circulation, in WT rats pretreated with 
low dose of MK (2.5 mg/kg) and PR (15 mg/kg), were similar confirming similar Mrp1 inhibition 
by these inhibitors at a 5-6-fold dose difference. The AH MTX levels in WT rats administered 
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with PR high dose (25 mg/kg) were significantly higher compared to that seen in WT rats 
pretreated with MK high dose (5 mg/kg) (Fig. 3.7C). But, the DAH of MTX in WT rats treated with 
MK (5 mg/kg) was significantly higher compared to that observed in rats treated with PR (25 
mg/kg) (Fig. 3.7D). This could be attributed to the higher MTX levels in plasma of rats pretreated 
with PR (25 mg/kg) compared to that seen in rats treated with MK (5 mg/kg) (Fig. 3.6B). These 
results support and corroborate the earlier literature reports which demonstrate effective inhibition 
of Mrp1 activity in the BBB and other blood-organ barriers by MK (100,101). 
c. Blood-to-VH penetration of MTX 
In both WT and Mrp1 KO rats, a dose related VH MTX levels were observed at the 60 min time 
point (Fig. 3.8A). In the 4mg/kg dose study, the MTX concentrations in the VH of Mrp1 KO rats 
Fig. 3.8: The vitreous humor (VH) MTX levels (A&C) and VH to plasma distribution ratio of MTX (DVH) (B&D) 
in the Mrp1 KO rats and/or WT rats in different treatment groups. * - indicates significant difference at p<0.05, 
between WT or Mrp1 KO 4 mg/kg vs WT or Mrp1 KO 8 mg/kg, at same time point; σ - indicates significant 
difference at p<0.05, between WT vs Mrp1 KO, at same dose and time point; Ф -significantly different from WT 
rats treated with MTX (4 mg/kg) alone, at 60 min (p<0.05); φ- significantly different from Mrp1 KO rats treated 
with MTX (4 mg/kg) alone, at 60 min; ᴪ - significantly different from all (p<0.05) (mean ± SEM, n=6). 
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were significantly higher (p<0.05), at the 60 min time-point, compared to that seen in WT rats 
(Fig. 3.8A). Hence, the VH to plasma MTX distribution ratio (DVH) in Mrp1 KO rats, treated with 
the lower dose was significantly higher (p<0.05) compared to that of the WT rats, at 60 min (Fig. 
3.8B). This suggests that the penetration of MTX across, the BRB, is influenced by Mrp1 efflux  
protein activity. These results verify the previous literature reports that demonstrate the expression 
of Mrp1 efflux protein on the BRB (78). The MTX concentrations in the VH of the WT and Mrp1 
KO rats, at 8 mg/kg dose study, were not statistically different (Fig. 3.8A). Hence, no significant 
difference was noticed in the DVH of drug in WT and Mrp1 KO rats at both time intervals post 
higher dose treatment (Fig. 3.8B). Reports in the literature demonstrated that MTX induce 
reversible optic neuropathies, at higher doses (125). The ERG studies also confirmed that MTX, 
at high dose (8 mg/kg) resulted in the damage to the retina architecture and functions. Hence, the 
damaged retina could have accommodated MTX in the VH and thus, resulted in similar DVH of 
MTX in WT and Mrp1 KO rats.  
 Considering the remarkable impact of Mrp1 activity at the 60 min time point post 1 mg/kg 
MTX dose treatment, this dose and time point was selected to study the effect of Mrp1 inhibition 
by MK and PR, on the penetration of MTX across the BRB. Significantly higher (p<0.05) MTX 
levels were observed in the VH of rats treated with MTX and Mrp1 inhibitors (MK and PR), over 
that seen in the rats administered with MTX alone (4 mg/kg) (Fig. 3.8C). Hence, significantly 
higher VH to plasma MTX distribution ratio (DVH) in rats receiving MK or PR (at both doses) 
were seen, compared to that observed in the rats dosed with MTX alone (4 mg/kg) (p<0.05) (Fig. 
3.8D). The DVH of MTX in WT rats co-administered with MK or PR and MTX were about 2-folds 
higher compared to that noted in Mrp1 KO rats (at 4 mg/kg and at 60 min) (Fig 3.8A and Fig. 
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3.8D). This can be owed to effective inhibition of Oat3, beside Mrp1, in the BRB by MK and PR. 
The Oat3, an influx transporter positioned on the apical membrane of inner BRB blood vessels, 
keep the substrate drug in the blood while the Mrp1, an efflux protein located on the basolateral 
membrane of the RPE (away from VH), prevent the transportation of substrate drugs across the 
outer BRB into the VH (100-102). Thus, effective inhibition of these transporter proteins by MK 
and PR allowed greater drug penetration into the VH from blood. These results demonstrate that 
the effective modulation of Mrp1 activity in the BRB, by MK and PR, improved the blood-VH 
penetration of MTX. 
3.4 Conclusion 
The over-all results from the comparative ocular distribution studies in WT, P-gp KO and Mrp1 
KO rats delineated the influence of P-gp efflux transporter and Mrp1 efflux protein on the blood-
ocular penetration of PTX and MTX, respectively. A dose related effect of PTX and MTX were 
noticed with respect to the impact of P-gp/Mrp1 activity in the BOBs. The effect of P-gp and Mrp1 
on the penetration of these anticancer drugs across the BOB were more evident at the lower dose. 
The improved distribution of PTX and MTX into the AH and VH from the systemic circulation in 
the P-gp KO and Mrp1 KO rats, illustrates the existence and magnitude of the efflux proteins (P-
gp and Mrp1) barrier characteristics in the BAB and the BRB. An improvement in the blood ocular 
penetration of PTX and MTX, in the WT rats, in the presence of specific P-gp inhibitors (EQ and 
TQ) and Mrp1 inhibitors (MK and PR) point to effective inhibition of P-gp and Mrp1 mediated 
efflux activity in the BAB and BRB. The ERG studies indicated that both substrates, at higher 
dose, induced alterations in the retina functions. However, the interactions of PTX/MTX, at the 
lower dose, and P-gp inhibitors (EQ/TQ) or Mrp1 inhibitors (MK and PR) did not show any toxic 
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effect on the retinal functions. The findings also suggest that prolonged exposure to the 
chemotherapeutic agents above a particular dose can lead to damage to the retinal tissue. 
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CHAPTER 4 
COADMINISTRATION OF TOPICAL OCULAR INSERTS OF SPECIFIC 
INHIBITOR MODULATES P-GP ACTIVITY IN THE BLOOD OCULAR BARRIERS AND 
IMPROVES BLOOD-TO-EYE PENETRATION OF SUBSTRATE ANTICANCER DRUG 
 
4.1.Introduction 
Ocular tumors such as retinoblastoma, uveal melanoma etc. are site- and life-threating 
ailments in pediatric and adult patients (126,127). Effective ocular chemotherapy is mainly 
compromised by P-glycoprotein (P-gp) mediated efflux transportation of chemotherapeutic agents, 
in the blood ocular barriers (BOB) (128). Upregulation of P-gp in the ocular tumors and its broad 
substrate specificity restricts the efficacy of the substrate anticancer drugs (128, 76-79). Numerous 
research investigations demonstrated enhanced substrate drug levels in the target organs by 
effective inhibition of the P-gp activity at specific blood-organ interface (90,91,129,130). In recent 
times, the third-generation specific P-gp inhibitors, elacridar (EQ) and tariquidar (TQ), were 
extensively studied to modulate the P-gp activity and to improve the substrate drug molecules 
penetration across the blood brain barrier or into the breast cancer cells (76, 97-99). It has been 
reported that concurrent intravenous or intravitreal administration of substrate drugs and inhibitors, 
like EQ/TQ demonstrated effective inhibition of P-gp activity in the blood aqueous barrier (BAB) 
and blood retinal barrier (BRB) (103-105,131). However, the penetration of substrate drug into 
non-specific organs due to the inhibition of P-gp activity in their plasma membrane is the major 
drawback associated with concurrent intravenous administration of substrate and inhibitors (132). 
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Previously, the contribution of topically administered first-generation P-gp inhibitors in 
improving the blood-ocular penetration of systemically and intravitreally administered substrates 
has been successfully investigated in New Zealand albino rabbits (106,107).   
Ocular drug delivery via topical application, however, is restricted by various 
physiological, anatomical, static and dynamic barriers (17-19). Most of the conventional 
ophthalmic dosage forms, upon topical application, are washed out from the precorneal space and 
thus results in poor ocular bioavailability (5-10%) (17-19). Enhancement in the viscosity and 
mucoadhesive properties of the formulations prolonged their ocular residence (133). Recently, 
topical ocular films were explored for sustained ocular drug delivery. They form drug depot in the 
vicinity of conjunctiva and sclera tissue and thereby favors drug penetration into deeper ocular 
tissues, probably through conjunctiva-sclera pathway (20,21). 
In the current research, EQ and TQ loaded melt cast films were developed using 
thermoplastic polymers, PolyOx® WSR N-10 (PEO), and Eudragit® FS 100 (FS), for the topical 
ocular application. Physicochemical properties and transocular membrane permeability of EQ and 
TQ from the inserts were evaluated. Further, for the first time, the impact of coadministration of 
EQ/TQ topical ocular inserts on blood ocular penetration of substrate anticancer drug, paclitaxel 
(PTX), by effective inhibition of P-gp activity in the BOB, was investigated in the Sprague Dawley 
(SD) rats. Electroretinography (ERG) studies and ultrastructure analyses of retinal pigmented 
epithelium (RPE) were conducted to determine the safety of PTX-EQ/TQ interactions on the 
structure and functions of retina.    
 
 
 
73 
 
4.2. Materials and Methods 
4.2.1. Chemicals 
PTX was procured from Sigma Aldrich (St. Louis, MO). EQ, TQ, were acquired from Alfa 
Aesar (Haverhill, MA). PEO N 10 [PolyOx® WSR N-10 (PEO N-10), MW: 100,000 Daltons] 
(PEO) and Eudragit® FS 100 (FS) were generously donated by Dow Chemical Company (Midland, 
MI) and Evonik (Darmstdat, Germany), respectively. All other chemicals were procured from 
Fisher Scientific (St. Louis, MO).  
4.2.2. Animal tissues 
Whole eyes of New Zealand albino rabbits were obtained from Pel-Freez Biologicals® 
(Rogers, AK). They were shipped overnight in Hanks Balanced Salt Solution (HBSS) over dry ice. 
On the day of receipt of Whole eye globes, corneas and sclera-retina-choroid (SRC) were excised 
and utilized in the relevant experiments. 
4.2.3. Animals 
Six to eight-week-old male wild type SD rats, were purchased from Horizon Discovery 
(Saint Louis, MO). They were allowed for free access to food and water. The animal experiments 
were performed according to the approved protocols of the University of Mississippi Institutional 
Animal Care and Use committee, the University of Tennessee Health Science Center Institutional 
Animal Care, and Use committee and the Association for Research in Vision and Ophthalmology 
statement for the Use of Animals in Ophthalmic and Vision Research. 
4.2.4. Preparation of EQ and TQ loaded films 
EQ and TQ loaded ocular films were prepared by melt cast technology. The physical mixtures of 
inhibitor/s (EQ or TQ) and polymer/s (PEO alone or PEO:FS (1:1 w/w)) were prepared by mixing 
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geometric proportions of accurately weighed excipients in the mortar with pestle. 
 
The physical mixture was then introduced into the center of 13 mm die placed on the brass plate, 
maintained at 70°C on the hot plate, and compressed with 13 mm punch to form a flat film of 10% 
w/w EQ or TQ load. The film was further heated for 2-3 min, cooled and cut into inserts of 1 mm 
x 1 mm x 0.2 mm or 2 mm x 1 mm x 0.2 mm dimensions, weighing approximately 1mg or 2 mg, 
for further experiments. The composition of the TQ and EQ films are given in Table 4.1.  
4.2.5. Analytical procedure to determine EQ and TQ  
 EQ content in the in vitro samples was estimated by high performance liquid 
chromatography-ultraviolet spectrometry (HPLC-UV) method. A mobile phase comprising 
acetonitrile (ACN) and 0.05 M ammonium acetate (45:55 % v/v), pH adjusted to 5.0 with 
orthophosphoric acid, was passed through a Luna® C18(2) 100 ℃ column (Phenomenex, 4.6 mm x 
250 mm; 5µ particle size), at a flow rate of 1 mL/min, by Waters HPLC system with 600 E 
controller pump. 25 µL of sample was injected to the flow of mobile phase by Waters 717 plus 
Table 4.1: Composition of elacridar and tariquidar film formulations and evaluation parameters 
Formulation  
Components (% w/w) 
Assay (%) 
Content 
Uniformity 
(%) 
PEO FS EQ TQ 
EQ PEO-FS 45 45 10 - 102.24 ± 4.92 101.42 ± 0.25 
TQ PEO 90 - - 10 99.44 ± 1.99 102.77 ± 3.86 
TQ PEO-FS 45 45 - 10 84.68 ± 1.15 75.84 ± 11.56 
EQ PEO 90 - 10 - 54.36 ± 1.36 57.04 ± 22.56 
- PEO, FS, EQ and TQ indicates poly ethylene oxide N10 (PolyOx® WSR N-10), Eudragit® FS 
100, elacridar and tariquidar, respectively. 
- EQ-PEO-FS, TQ-PEO-FS, EQ-PEO and TQ-PEO represents elacridar film with polyethylene 
oxide N10 and Eudragit® FS 100 polymers, tariquidar films with polyethylene oxide N10 and 
Eudragit® FS 100 polymers, elacridar film with polyethylene oxide N10 polymer and tariquidar 
films with polyethylene oxide N10 polymer, respectively 
- Weight of each film formulation was 200 mg 
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Autosampler and the column eluent was monitored at λmax (detection wavelength) of 254 nm using 
Waters 2487 dual λ absorbance detector. The peak response was integrated by an Agilent 3395 
integrator (131, 134).  
 TQ content was estimated in the samples using similar chromatographic conditions except 
the mobile phase consisted of acetonitrile (ACN) and 0.2 M ammonium (40:60 % v/v) and pH 
adjusted to 4.5 with glacial acetic acid. The column eluents were tested at λmax of 222 nm (131, 
76). 
4.2.6. Assay and content uniformity 
The assay of EQ or TQ ocular films was determined by dissolving the 13 mm film in 10 
mL of extracting solvent, equal volumes of dimethyl sulfoxide (DMSO) and methanol. Content 
uniformity was determined by dissolving four inserts randomly sliced from a single film, in 
extracting solvent. The samples were diluted and quantified for the EQ and TQ content using 
HPLC. 
4.2.7. Differential scanning calorimetry (DSC)  
DSC was performed to understand the thermal behavior and chemical compatibility of 
polymers and inhibitors. DSC thermograms for EQ, TQ, PEO, FS and 10% w/w inserts were 
obtained on DSC Q20 differential scanning calorimeter (TA instruments, USA). Appropriately 
weighed samples were sealed in aluminum pans and heated from 0oC to 270oC at 20 oC /min 
heating rate, under nitrogen purge (20 mL/min).  
4.2.8. In vitro release studies  
In vitro release behavior of EQ and TQ from EQ-PEO-FS and TQ-PEO ocular inserts of 
2mm x 1mm x 0.2 mm dimensions was tested, as reported earlier (20,21), cross standard US 100 
mesh sieve in 20 mL scintillation vials. The insert was taken in 20 mL scintillation vial and a US 
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100 mesh sieve was placed on the films. 10 mL release medium (2.5 % w/v RMβCD and 1 % w/v 
Tween 80 in phosphate buffer solution (PBS) (pH 7.4) was added to the vial and a stir bar was 
placed over the sieve. The whole set up was placed in a thermostatic water bath (Fisherbrand™ 
Isotemp™ Advanced Stirring Hotplate, HN), maintained at 34°C and under constant stirring, for 
2h. 1 mL sample was collected at pre-determined time intervals and replenished with same volume 
of fresh medium. The samples were analyzed for the EQ/TQ content using HPLC.  
4.2.9. Transocular membrane permeability studies 
4.2.9.1. In vitro transcorneal permeation study    
In vitro transcorneal transport studies were performed using the corneas excised from 
whole eye globes of New Zealand male albino rabbits. The corneas were mounted on the receptor 
compartment of the Valia-Chien cells (PermeGear, Inc., Hellertown, PA), such that the epithelial 
side face towards the donor compartment. The receptor compartment was filled with 5 mL media 
(2.5 % w/v RMβCD and 1 % w/v Tween 80 in PBS (pH 7.4). 2 mg of EQ-PEO-FS or TQ-PEO 
insert (equivalent to 0.2 mg of EQ/TQ) was placed on corneas and wetted with 50 µL of media in 
the donor compartment. The diffusion cells were maintained at 34°C with the help of a circulating 
water bath for 3h study period. Aliquots of 600 µL were withdrawn from receptor compartment at 
specific time intervals and replaced with same volume of fresh medium. EQ/TQ content in the 
samples and cornea tissues were estimated using HPLC.  
4.2.9.2. In vitro trans-SCR permeability study  
In vitro trans-SCR (sclera-choroidal RPE) permeability of EQ/TQ was determined by using 
freshly excised scleral tissue with the retinal pigmental epithelium and choroid layers, from whole 
rabbit eyes. SCR was mounted on receiver compartment of Valia-Chien cells (Perme Gear, Inc®) 
such that the scleral side was facing to the donor compartment and the RPE-choroidal layers were 
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located towards the receptor compartment. 5 mL of media (2.5 % w/v RMβCD and 1 % w/v Tween 
80 in PBS (pH 7.4) was filled in the receptor chamber. 2 mg of EQ-PEO-FS or TQ-PEO insert 
(equivalent to 0.2 mg of EQ/TQ) was placed on sclera and wetted with 50 µL of media in the donor 
compartment. The diffusion cells were maintained at 34°C with the help of a circulating water bath 
for 3h study period. Aliquots of 600 µL were withdrawn from receiver compartment at specific 
time intervals and replaced with same volume of fresh medium. EQ/TQ content in the samples and 
SCR tissue were estimated using HPLC. 
4.2.10. Data Analysis 
The transocular permeability parameters of EQ/TQ such as the cumulative amount of drug 
permeated (Mn), steady state flux (J) and the apparent permeability coefﬁcient (Papp) were estimated as 
previously reported (135). Equations 1 was used to integrate the cumulative amount of EQ/TQ permeated 
across the cornea or SCR. 
 	 	∑                                     (1) 
Where: n specified sample time interval (n = 1, 2, 3….8 corresponding to 15, 30, 45….180 min 
respectively); Vr and VS indicates the media volume in the receptor compartments (mL) and sample 
the volume collected at the nth time interval (mL); and Cr(n) represents the EQ/TQ concentration in 
the receptor compartment medium at nth time interval (µg/mL). 
 The slope of the cumulative EQ/TQ permeated vs. time (t) plot was determined to calculate 
the steady-state flux (SSF) (J) of EQ/TQ was using equation 2: 
                                                   / "/#                                          (2) 
Where M and A specifies the cumulative amount of drug transported and the surface area of the 
cornea or SCR utilized in the experiment (0.636 cm2). 
3. The apparent permeability of EQ/TQ across the cornea or SCR was determined from the ratio of 
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steady state flux (J) and EQ/TQ amount in the donor compartment (Cd) (Eq. (3)) (26, 30). 
               $%&&  '()	*+,∗./                                                          (3) 
4.2.11. P-gp protein expression by western blotting 
The expression of P-gp protein in the BAB and BRB of the SD rats was studied by western 
blotting. The SD rats were euthanized with excess intraperitoneal (IP) dose of ketamine (35 mg/kg) 
and xylazine (3.5 mg/kg) combination (n=6), the eyes were enucleated, and immediately the ocular 
tissue (Iris Ciliary (IC) and Retina choroid (RC)) samples were collected. IC and RC tissues lysates 
were prepared using 2X lysis buffer (Cell Signaling Technology, USA). Tissue lysates were 
measured for protein concentrations by Bradford assay (Bio-Rad USA). 20 µg of proteins, from 
each tissue lysate, were taken into the wells of 10% SDS-PAGE mini-gels (Bio-Rad, USA) and 
electrophoresed. Then proteins were transferred to nylon membranes (Cell Signaling Technology, 
USA) according to standard western blot protocol.  These membranes were blocked in 5% non-fat 
dried milk in 1X TBST [20 mM Tris–HCl (pH 7.5), 137 mM NaCl and 0.1% (v ⁄ v) Tween 20] for 
1h at room temperature. Blots were kept overnight with primary antibody MDR1/ABCB1 (Cat # 
13978 Cell Signaling Technology) as per the manufacturers protocol. After washing the 
membranes with 1X TBST, they were probed with anti-rabbit secondary antibody conjugated to 
HRP (Cat # 7074 Cell Signaling Technology) for 1h. To ensure equal loading, samples were added 
with β actin antibody (Cell Signaling Technology, USA). The blots were developed with signal 
flame enhanced chemiluminescence (ECL) TM kit (Cell Signaling Technology, USA). The images 
were captured, processed and analyzed on ChemiDoCTM MP imaging system (Bio-Rad, USA). 
Protein band area was computed by using ImageJ and, the ratio of P-gp band area and the 
corresponding β-actin band area was calculated as relative P-gp protein intensity. 
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4.2.12. Electroretinography  
To determine the PTX-EQ or TQ interactions with the retina functions, electroretinography 
(ERG) studies were performed in SD rats. 12 SD rats were divided into 2 groups and one group 
was topically administered with 1 mg EQ-PEO-FS insert (equivalent to 0.1 mg EQ) in each eye 
while the other group received 1 mg TQ-PEO insert (equivalent to 0.1 mg TQ) in each eye. During 
the administration of EQ or TQ inserts, the rats were partially anesthetized with ketamine (35 
mg/kg) and xylazine (3.5 mg/kg) combination through IP route. Post 30 min EQ/TQ administration 
in the eyes of the rats in both the groups, they were injected with a specific volume of 3 mg/mL 
PTX solution (equivalent 1 mg/kg intravenous dose).  
 ERG was performed as per the standard protocols (115,116). The overnight dark-
adapted rats were anesthetized with an I.P. injection of ketamine and xylazine combination. Both 
the corneas were anesthetized with topical 0.5% proparacaine hydrochloride, the pupil was dilated 
with 1% tropicamide and gold ring electrodes of 2-3 mm diameter (Roland Consult, Stasche & 
Finger GmbH), were placed on corneas. Stainless-steel surgical needles were inserted 
subcutaneously in the forehead and back leg to serve as reference and ground electrodes 
respectively. Both the eyes were exposed to Ganzfeld light source flashes of different intensities 
(from −4.0 Log units to 2.88 Log units) and the dark-adapted ERG patterns were measured. The 
baseline a- wave and b-wave amplitudes were recorded in the rats before the administration of 
EQ/TQ inserts. The differences in the a- and b- waves amplitudes recorded as baseline and at the 
of 6h or 12h post PTX (1 mg/kg) treatment were reported as percentage change in the amplitude.   
4.2.13. Ultrastructural analyses of retina pigmental epithelium  
Ultrastructural analyses of the retina was performed, as per the standard protocols (115, 
131), to evaluate the PTX-EQ/TQ interactions with the structure of the retina. Post ERG studies, 
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the rats from 2 treatment groups were euthanized with excess of ketamine and xylazine 
combination, the eyes were enucleated and were fixed with a 2% paraformaldehyde and 2% 
glutaraldehyde mixture in 0.1 M phosphate buffer. These eyes were then embedded in 
Araldite/Embed812 (Electron Microscopy Sciences) and the anterior-posterior axis of the eye were 
aligned parallel to the cutting surface block and sections of one-micron thick were sliced through 
the posterior pole of each eye. The tissue sections were stained in Toluidine Blue O and then seen 
under a Nikon Eclipse 800 microscope to select the suitable tissues section area for ultrastructural 
analyses of RPE and retinal blood vessels. These ultrathin sections were observed for any structural 
changes in the RPE or the retinal vasculature under JEOL JEM1200EX II electron microscope at 
high magnification. 
4.2.14. Ocular distribution 
Ocular distribution studies were undertaken in male SD rats to establish the impact of co-
administration of specific P-gp inhibitor loaded topical ocular inserts on the blood ocular 
penetration of PTX through effective modulation of P-gp activity in the BOB. No gender 
dependent transporter protein expression in the ocular tissues were reported in the literature, thus, 
the current study was conducted in only male SD rats. 60 SD rats were divided into 2 treatment 
groups with equal number of rats. Each rat in the first group was administered with 1 mg of EQ-
PEO-FS insert (equivalent to 0.1 mg EQ) topically in each eye. The second group rats were 
administered with topical 1 mg TQ-PEO insert (equivalent to 0.1 mg TQ) in each eye. The rats in 
each group were partially anesthetized with IP ketamine (35 mg/kg) and xylazine (3.5 mg/kg) 
combination before the administration of EQ/TQ insert, and they were conscious in 5-10 min post 
EQ/TQ administration. After 30 min from the EQ/TQ administration, rats in two groups were 
administered with 1 mg/kg dose of PTX intravenously through tail vein. At 1, 2, 4, 6 and 12h post 
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PTX treatment, rats (n=6 at each time point) from each group were anesthetized with an I.P. 
administration of ketamine (35 mg/kg) and xylazine (3.5 mg/kg) mixture, blood was collected via 
cardiac puncture and were euthanized with excess of ketamine and xylazine combination through 
I.P. route. The eyes were enucleated immediately. Aqueous humor (AH) and vitreous humor (VH) 
were collected from both eyes of each rat and was pooled. The blood samples collected were 
immediately centrifuged at 10,000 rpm for 5 min and the plasma was separated. Plasma, AH and 
VH samples were stored at -80oC until analysis.  
 Another group of 12 SD rats, not pretreated with either EQ or TQ insert, were 
injected with 1 mg/kg dose of PTX through tail vein. At 1h and 2h post PTX dosing, the rats (n=6 
at each time point) were processed similarly as mentioned earlier and the plasma, AH and VH 
samples were collected and stored at -80oC until analysis.  
4.2.15. Sample Preparation 
10 µL, 2.5 µL, and 5 µL of 1 µg/mL docetaxel (DTX) (internal standard (IS) for PTX) and 
1 µg/mL loperamide (LOP) (internal standard (IS) for EQ and TQ) solutions were added to 80 µL 
plasma, 20 µL AH and 40 µL VH tissue samples, respectively. The proteins in 1 part of sample 
tissue matrix was precipitated with 2 volumes of ice-cold acetonitrile to extract PTX or EQ and 
TQ and IS. These samples were vortexed, centrifuged at 13000 rpm for 15 min and the supernatant 
solution was separated. The PTX, EQ, TQ and their respective IS in the supernatant solution (2 
μL) were quantified by the following LC/MS method. The extraction efficiency (EE), limit of 
detection (LOD) and linearity of PTX, EQ and TQ in plasma (10-100 ng/mL), AH (0.5-40 ng/mL) 
and VH (0.5-20 ng/mL) was evaluated separately. 
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4.2.16. Quantification of PTX, EQ and TQ in the biological matrix  
The quantity of PTX, EQ and TQ in the plasma, the AH and the VH samples were 
determined with the ACQUITY UPLC® I-Class System (Waters Corporation, Milford, MA, USA) 
connected to Waters Xevo TQ-S triple quadrupole tandem mass spectrometer with an electrospray 
ionization (ESI). Data acquisition and processing were controlled by Waters Xevo TQ-S 
quantitative analysis TargetLynx software and MassLynx mass spectrometry software, 
respectively.  
 Separation of PTX was achieved on an Acquity UPLCTM Cortecs C18 (2.1x100 
mm; 2.7 µm) column with operations were accomplished using a C18 column (Acquity UPLC® 
BEH C18 100 mm×2.1 m, 1.7µm particle size). The mobile phase comprised of water (A) and 
acetonitrile (B), both containing 0.1 % formic acid, at a flow rate of 0.7 mL/min, which were 
applied in the following gradient elution: 0 min, 55 % A: 45% B, in next 2.5 min to 50% B, and 
next 0.2 min to 100 % B, and then to 55% A for next 2.5 min. Each run was followed by a 3 min 
wash with 100 % acetonitrile, and an equilibration period of 1 min. The column temperature was 
set at 50 °C. Two microliters of sample was injected into the column and the effluent was directed 
into the ESI probe (source) operated using following parameters: source temperature 60°C, 
desolvation temperature 600°C, capillary voltage 2.0 kV, cone voltage 30 V, nebulizer pressure-7 
bar, desolvation gas flow 1200 L/h N2 and cone gas flow 150 L/h N2. The collision energies ranging 
from 20 to 64 eV were optimized, for individual analytes. Argon served as the collision gas. All 
the instrument operations were controlled by MassLynx software (version 4.1, Waters, Milford, 
MA, USA). Mass spectra of each sample was acquired in positive mode. The precursor to daughter 
ions transitions (quantifier ion to qualifier ions transitions) of PTX (m/z 854.31 → m/z 286.14, 
122.08, 195.06) and DTX m/z 808.37 → m/z 527.23, 327.15, 105.06) was monitored in multiple 
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reaction monitoring (MRM) mode. The compounds were confirmed in each spectrum by the three 
daughter ions, each for PTX and DTX. 
 The peaks of the EQ, TQ and LOP (IS) were quantified with respect to the specific 
mass to charge (m/z) values (m/z 564, 647 and 477 for EQ, TQ and LOP, respectively). The 
samples were eluted through BEH C18 (2.1 x 100 mm, 1.7 µm) column and separated using an 
isocratic mobile phase consisting of with 0.1% v/v formic acid and water with 0.1% v/v formic 
acid. The method showed a limit of detection (LOD) and limit quantification of (LOQ) of 0.1 
ng/mL for EQ and TQ. 
4.2.17. Data Interpretation  
PTX distribution into the AH and VH from plasma was calculated according to equations 
1 & 2 respectively, 
012  +3456%673	38	9:;	7	=>	?/@A+3456%673	38	9:;	7	9(%@%	?/@A                      (Eq. 1) 
0B2  +3456%673	38	9:;	7	C>	?/@A+3456%673	38	9:;	7	9(%@%	?/@A                      (Eq. 2) 
Where, DAH and DVH designates the distribution ratios delineating the penetration of PTX 
from plasma into AH and VH, respectively. 
4.2.18. Statistical analysis  
The data from ERG and ocular distribution studies were processed through one-way 
analysis of variance (ANOVA) and Tukey’s post hoc HSD (GraphPad Software, San Diego 
California, USA), to establish the statistical signiﬁcance. The p < 0.05 were considered statistically 
significant. 
4.3. Results and Discussion  
Melt-cast method, a simple and solvent free technique, was adopted to fabricate the ocular 
films of EQ and TQ (20, 21). In these ocular films, molecular level drug entrapment in carrier 
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matrix results in higher drug loading. Unlike the conventional ophthalmic dosage forms, the use 
of excipients such as preservatives are not necessary in the melt cast ocular films (26, 27). PEO 
and FS, thermoplastic polymers, were used as matrix forming materials due to the thermogelling 
property and pH 7.4 dependent drug releasing characteristic, respectively (20, 136).   
4.3.1. Assay and content uniformity 
The assay and content uniformity of the EQ and TQ films are detailed in Table 4.1. EQ-
PEO film showed low assay (54.3%) and content uniformity (57%) due to the manufacturing issues 
like sticking of EQ to motor and picking by 13 mm punch during the film preparation (Table 4.1). 
No such manufacturing issues were noticed while developing EQ-PEO-FS film and thus, resulted 
in ~ 100% assay and content uniformity (Table 4.1). On the other hand, loss of TQ was noticed in 
the development of TQ-PEO-FS film and resulted in low assay (84.68%) and content uniformity 
(75.84%) (Table 4.1). TQ-PEO film showed acceptable 99.44% assay with uniform distribution of 
TQ in the PEO matrix suggesting the lack of sticking and picking issues while manufacturing 
(Table 4.1). EQ-PEO-FS and TQ-PEO films with acceptable assay and uniform distribution of 
compounds in the polymeric matrix were considered for further studies.  
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4.3.2. DSC  
DSC studies were performed to investigate the thermal behavior and excipient 
compatibility of TQ-PEO and EQ-PEO-FS ocular inserts. DSC thermograms of EQ, TQ, PEO, FS 
and PEO-FS (1:1 w/w), TQ-PEO and EQ-PEO-FS are displayed in Figure 4.1. The endothermic 
peaks seen at 69.49°C and 55.99°C in the PEO and FS thermograms, respectively, corresponds to 
their melting points (Fig. 4.1). Pure EQ and TQ showed the melting peaks at 227.21°C and 
229.03°C, respectively (Fig 4.1). TQ-PEO and EQ-PEO-FS ocular inserts exhibited a melting 
point peak at 67°C. The absence of native endothermic peak of Eq and TQ in the films indicated 
the reduction in crystallinity of inhibitors in the polymeric frameworks (Fig. 4.1). No significant 
 
Figure 4.1: DSC thermograms of PEO N10, FS, EQ, TQ, EQ-PEO-FS insert and TQ-PEO insert. 
86 
 
shifts in the characteristic melting points of the polymers and inhibitors in the ocular inserts 
suggested absence of chemical interactions between the film components.   
4.3.3. In vitro release of EQ and TQ 
In vitro release profile of EQ and TQ from ocular inserts are presented in Figure 4.2. In 
vitro release behavior of these P-gp inhibitors were studied in PBS (pH 7.4) with 2.5 % w/v 
RMβCD and 1 % w/v Tween 80 (pH 7.4) due to relatively high solubility of both EQ (20.14 ± 
0.93 µg/mL) and TQ (12.16 ± 0.30 µg/mL). At the end of 2h, the % cumulative release of EQ and 
TQ, from EQ-PEO-FS and TQ-PEO inserts, were 92.35 ± 4.57 and 87.54 ± 2.56%, respectively 
(Fig. 4.2). The release of EQ from EQ-PEO-FS insert was comparatively slower than TQ from 
TQ-PEO insert (Fig. 4.2) which could be attributed to the presence of FS polymer, that helps drug 
release only at pH 7.0, in EQ-PEO-FS insert (136).    
 
 
 
Figure 4.2: In vitro release profiles of EQ and TQ from EQ-PEO-FS and TQ-PEO ocular inserts, respectively 
(mean ± SD; n=6) 
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4.3.4. Transocular permeability    
In vitro transocular membrane permeability parameters of EQ and TQ are given in Table 
4.2. Both EQ and TQ showed transcorneal permeability but no penetration was noticed across the 
SCR (Table 4.2). The steady state flux and Papp of TQ-PEO inserts (0.040 ± 0.01 µg/cm2/min and 
5.6 ± 2.4 x 10-6 cm/s), across the rabbit cornea, were significantly higher than EQ-PEO-FS inserts 
(0.016 ± 0.003 µg/cm2/min and 1.3 ± 0.3 x 10-6 cm/s). This could be attributed to the higher Log 
D7.4 and topological polar surface area of TQ (5.39 & 111.25 A2) compared to EQ (3.9 & 89.1 A2). 
It has been demonstrated in the literature that the transmembrane permeability of a compound 
decreases with the decrease in Log D7.4 and the compounds with higher polar surface area can 
penetrate through the hydrophilic stroma layer in the cornea (137, 138). Additionally, the slow 
release of EQ from EQ-PEO-FS inserts, compared to TQ from TQ-PEO insert, could have resulted 
in its lower transcorneal permeation. The SCR tissues treated with corresponding inserts showed 
EQ and TQ levels suggesting the lateral diffusion of these P-gp inhibitors in the sclera, but they 
Table 4.2: In vitro transocular membrane permeation parameters of elacridar and tariquidar from film 
formulations (mean ± SEM; n=3) 
Films 
Transcorneal permeability 
parameters 
Trans-SCR permeability 
parameters 
Flux 
(µg/cm2/min) 
P
app
 x 106
 
(cm/s) 
Amount in 
cornea (µg) 
Flux 
(µg/cm2/min) 
P
app
x 106
 
(cm/s) 
Amount in 
SRC (µg) 
10 % w/w 
EQ- PEO-FS 
0.016 ± 0.003 1.3 ± 0.3 30.7 ± 9.6 NS NS 156.9 ± 3.44 
10 % w/w 
TQ- PEO 
0.04 ± 0.01* 5.9 ± 2.4* 36.3 ± 0.4 NS NS 112.7 ± 0.5 
- PEO, FS, EQ and TQ indicates poly ethylene oxide N10 (PolyOx® WSR N-10), Eudragit® FS 100, elacridar 
and tariquidar, respectively. 
- EQ-PEO-FS and TQ-PEO represents elacridar film with polyethylene oxide N10 and Eudragit® FS 100 
polymers, and tariquidar films with polyethylene oxide N10 polymer, respectively 
- SCR and Papp represents sclera-choroidal RPE and apparent permeability coefficient, respectively   
- Weight of each film formulation was 200 mg 
- *-indicates level of significance at p<0.05between transocular membrane permeability of EQ-PEO-FS and 
TQ-PEO  
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did not penetrate across the choroidal RPE (Table 4.2). The levels of EQ in the SCR tissue was 
significantly higher compared to TQ in TQ-PEO treated SCR tissues which could be due to the 
high the molecular weight of TQ (646 g/moL), compared to EQ (563 g/moL) (Table 4.2). Earlier 
reports demonstrated poor sclera penetration of high molecular weight compounds (20, 21).  
4.3.5. Electroretinography (ERG) 
ERG was carried out to investigate any toxic effects of PTX-EQ/TQ ocular insert 
interactions on the functions of photoreceptor cells in the outer segment of the retina and inner 
retinal cells. The a-wave and b-wave recordings noted in the ERG represents the functioning of 
photoreceptor cells and bipolar/Müller cells, respectively. Any changes in the a- and b-wave 
patterns indicate the damage to the outer retina and the inner retina (114-116). The percent change 
in the amplitude of a- and b-wave examined in the SD rats are delineated in Figure 4.3.  
 No significant changes in the a- and b-wave amplitudes were observed, with respect 
to baseline measurements, in the rats treated with EQ-PEO-FS (equivalent EQ 100µg/eye) and 
 
Figure 4.3: A) Percent changes in the amplitude of ERG wave patterns recorded in the EQ-PEO-FS and TQ-PEO 
treated rats, at 6h and 12h post PTX (1 mg/kg) intravenous administration (mean ± SEM; n=3). 
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TQ-PEO (equivalent TQ100µg/eye) ocular inserts, post 6h and 12h PTX (1 mg/kg) intravenous 
administration, (Fig. 4.3). Thus, ERG studies confirmed that the tested doses of EQ-PEO-FS, TQ-
PEO, and PTX did not induce any toxic effects on the functions of the retina.   
4.3.6. Ultrastructure analysis of RPE 
Figure 4.4 illustrates the ultrastructure of the RPE in rats co-administered with PTX and 
EQ-PEO-FS or TQ-PEO. RPE was observed under TEM for any morphological changes in 
choriocapillaris (Ch), Bruch’s membrane (BM), basolateral infoldings of RPE (BNF), pigmented 
granules (PG), and RPE nucleus. Diffused Ch, reduced BM thickness, absence of BNF, loss of 
pigmented granules (PG), and appearance of vacuoles in the RPE indicates the damage to retina 
architecture (139,140).  No such observations were noticed in the ultrastructure of RPE in rats 
topically administered with EQ-PEO-FS and TQ-PEO ocular inserts, at the end of 6h and 12h post 
PTX (1 mg/kg) IV administration (Fig. 4.4). Moreover, the ultrastructure of RPE in rats pretreated 
with EQ ocular insert were not different from those treated with TQ-PEO insert (Fig. 4.4). These 
findings suggested that the PTX-EQ/TQ interactions, at tested doses, did not compromise the 
structural integrity of retina. 
4.3.7. Ocular distribution 
Ocular distribution studies were performed to investigate the potential of topical ocular 
delivery of EQ-PEO-FS and TQ-PEO inserts to improve the blood-ocular penetration of substrate 
anticancer drug, PTX, by effective modulation of P-gp activity in the BOB. To ensure the 
inhibition of P-gp activity in the BOB, the rats were pretreated with EQ or TQ inserts 30 min prior 
to PTX dosing. The ocular pharmacokinetic profile of PTX in the rats co-administered with topical 
EQ and/or TQ ocular inserts is represented in Figure 4.5. The ocular pharmacokinetic parameters 
of PTX and P-gp inhibitors (EQ/TQ) are enumerated in Table 4.3 and Table 4.4, respectively.  
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Plasma PTX concentration profile seen in the rats from both EQ-PEO-FS and TQ-PEO 
groups were not statistically different (Fig. 4.5A). The AH PTX concentration profile seen in the 
rats treated with TQ inserts were significantly higher (p<0.05), till 4h post PTX administration, 
over that seen in EQ treated rats (Fig. 4.5B). Similarly, the DAH PTX observed in rats treated with 
TQ-PEO inserts were comparatively higher (p<0.05), in first 4h post PTX injection, than that 
noticed in the rats administered with EQ-PEO-FS ocular inserts (Fig. 4.5C). The PTX levels in the 
 
Figure 4.5: Pharmacokinetic profile of PTX in A) plasma, B) AH and E) VH of rats co-administered with EQ-PEO-
FS and TQ-PEO topical ocular inserts. D) Distribution of PTX from plasma to AH (DAH) and VH (DVH) in rats 
treated with intravenous PTX (1 mg/kg) alone and C) DAH, and F) DVH of PTX in rats co-administered with EQ and 
TQ ocular inserts (mean ± SEM; n=6). 
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AH of rats treated with PTX (1 mg/kg) alone were below the detectable limits whereas DAH PTX 
in both EQ and TQ pretreated rats were significantly higher (p<0.05) compared to that found in 
these rats and confirmed the effective inhibition of P-gp activity in the BAB (Fig. 4.5C & Fig. 
4.5D). These results corroborate with the earlier literature reports which demonstrated the 
enhanced penetration of substrate drug into the AH due to the effective modulation of the P-gp 
expression in the BAB, post concurrent intravenous or intravitreal administration of P-gp substrate 
and inhibitor (103,104, 131). The PTX profiles in the VH of rats administered topically with either 
Table 4.3: Ocular pharmacokinetic parameters of paclitaxel post intravenous administration in wild type rats 
co-administered with topical ocular films of EQ and TQ (mean ± SEM; n=6) 
Pharmacokinetic 
parameters 
PTX (1 mg//kg) + EQ 
(100 µg/eye) 
PTX (1 mg//kg) + TQ (100 
µg/eye) 
AH VH AH VH 
AUC0-12  
 (ng h/mL) 
31.5 ± 2.5 35.3 ± 4.6 39.5 ± 2.3 34.7 ± 1.6 
t ½ (h) 2.4 ± 0.4 2.3 ± 0.5 1.9 ± 0.2 2.0 ± 0.3 
MRT (h) 3.1 ± 0.4 3.1 ± 0.3 3.0 ± 0.2 3.0 ± 0.4 
- PTX, EQ, TQ, AH and VH indicates paclitaxel, elacridar, tariquidar, aqueous humor and vitreous 
humor, respectively 
- AUC, t ½ and MRT represents area under curve, elimination half life and mean residence time, 
respectively  
Table 4.4: Ocular pharmacokinetics of EQ and TQ in wild type rats administered with topical ocular film 
formulation (mean ± SEM; n=6) 
Pharmacokinetic 
parameters 
EQ (100 µg/eye) TQ (100 µg/eye) 
AH VH AH VH 
AUC0-12 (ng h/mL) 77.0 ± 2.8* 82.9 ± 4.6* 36.5 ± 2.8 12.5 ± 1.1 
t ½ (h) 2.8 ± 0.5 4.2 ± 0.8* 2.6 ± 0.4 1.8 ± 0.6 
MRT (h) 4.5 ± 0.8 5.2 ± 0.7* 5.8 ± 0.6 3.5 ± 0.3 
- EQ, TQ, AH and VH indicates elacridar, tariquidar, aqueous humor and vitreous humor, respectively 
- AUC, t ½ and MRT represents area under curve, elimination half life and mean residence time, 
respectively  
- *-indicates the level of significance at p<0.05 between pharmacokinetic parameters seen EQ (100 
µg/eye) and TQ (100 µg/eye) treated rats 
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EQ-PEO-FS and TQ-PEO ocular inserts were similar (Fig. 4.5E). Thus, the DVH PTX in both EQ 
and TQ treated rats were not statistically different (Fig. 4.5F). On the other hand, no drug 
penetration was noticed from plasma to VH of the rats administered with PTX alone (Fig. 4.5D). 
Hence, the DVH PTX in rats from both EQ-PEO-FS and TQ-PEO treatment groups were 
significantly higher (p<0.05) compared to the rats treated with PTX alone suggesting an improved 
blood-to-VH penetration of substrate anticancer drug by inhibiting the P-gp activity in the BRB, 
as reported in the earlier literature (105-107,131).    
 AUC of PTX in the AH of rats administered with TQ (39.5 ± 2.3 ng. h/mL) was 
slightly higher, but statistically not different, compared to that found in the rats treated with EQ 
(31.5 ± 2.5 ng. h/mL) (Table 4.3). The AUC of EQ and TQ in the AH of rats treated with P-gp 
inhibitor loaded ocular inserts were 77.5 ± 2.8 ng h/mL and 36.5 ± 2.8 ng h/mL, respectively (Table 
4.4). Even at ~2 fold lower AUC in AH of rats, TQ produced P-gp inhibitory effect similar to that 
of EQ and hence, no statistical difference was noticed in the AUC of PTX in the AH of rats from 
both EQ and TQ treatment groups. Similarly, at 2-6 fold lower AUC of TQ in VH, rats treated with 
TQ showed similar AUC of PTX in VH compared to that found in EQ treated rats (Table 4.3 and 
Table 4.4). These results can be related to high affinity of TQ (IC50 ≤ 0.05 µM) for P-gp compared 
to EQ (IC50 ≤ 0.1 µM) (95). It has been reported that the TQ modulates the P-gp efflux activity 
by blocking both drug and ATP binding sites, whereas, EQ blocks only the drug/substrate binding 
site in the P-gp structure (97,121). Hence, TQ showed effective inhibition of P-gp activity in the 
BOB and thus, enhanced the blood ocular penetration of PTX. 
  The DAH and the DVH of PTX in the rats treated with TQ-PEO insert was reduced, 
after 4h timepoint, while they sustained for 6h in the rats administered with EQ-PEO-FS inserts 
(Fig. 4.5C and Fig. 4.5F). This can be related to the elimination half-life (t ½) of TQ and EQ, in 
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the AH and the VH of rats. The t ½ of TQ in AH and VH was short whereas the EQ was longer in 
these ocular tissues (Table 4.4). The longer t ½ of EQ in the AH and the VH could be attributed to 
the slow release of EQ due to the presence of FS polymer which helps drug release at pH 7.0 (136, 
21). TQ-PEO and EQ-PEO-FS ocular inserts form a localized depot in the vicinity of conjunctival-
scleral tissue and thereby distribute into the deeper ocular compartments (20, 21). Hence, the MRT 
of EQ and TQ in the AH and VH was 4.5-5.8h ensuring the blood ocular penetration of PTX for 
6h by effective modulation of P-gp activity in the BOB (Table 4.4). 
4.4. Conclusion 
EQ and TQ loaded ocular inserts were successfully prepared by hot melt technology using PEO 
and FS thermoplastic polymers as matrix forming materials. TQ-PEO and EQ-PEO-FS ocular 
inserts showed acceptable assay and content uniformity. These ocular inserts showed ~ 90 % 
cumulative amount of EQ and TQ release in the in vitro release studies. Both EQ and TQ 
demonstrated the transcorneal permeability characteristics but poor trans-SCR permeability 
behavior. ERG studies and ultrastructure analyses of RPE revealed that the PTX, a substrate 
anticancer drug, and EQ/TQ interactions did not induce any toxic effects on the structure and 
functions of retina. Improved penetration of PTX into the AH and the VH from systemic 
circulation indicated the effective inhibition of P-gp activity in the BOB and exemplified the 
concurrent administration of topical ocular inserts of EQ/TQ, and intravenous anticancer substrate 
drug, as a potential strategy to enhance the ocular chemotherapy.   
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CHAPTER 5 
EYELID APPLICATION OF TRIAMCINOLONE PROTRANSFERSOME GEL FOR 
IMPROVED AND PROLONGED OCULAR DELIVERY 
 
5.1. Introduction  
Inflammation of the anterior and posterior segment ocular tissues are often associated with 
most of the eye ailments (140). Numerous steroidal and non-steroidal anti-inflammatory agents 
are being used for the management of ocular inflammations (141). Triamcinolone acetonide (TA) 
is a potent synthetic corticosteroid utilized to ameliorate the inflammation of ocular compartments 
(141). Currently, TA is available in the market as an intravitreal injection (Kenalog®, Kenacort®, 
Tricinolon®, Flutex®) for the treatment of deeper ocular tissue inflammations (140,142). Despite 
efficient therapy, intravitreal drug delivery encounters poor patient compliance due to post 
injection associated complications such as retinal detachment, postoperative infections etc. (19, 
144-146). Thus, topical ocular drug delivery is a more preferred route of administration. However, 
the ocular bioavailability of topically instilled drugs is hampered by various anatomical and 
physiological, constraints (19,133). 
 In recent times, drug delivery through the eyelid has been investigated as an 
alternative, noninvasive, drug delivery platform that can maintain and sustain therapeutic drug 
levels in the eye (147-150). The thickness of the skin and stratum corneum on the eyelid is very 
thin compared to the skin in any other region (148,149,151). The drug applied to the upper eyelid 
penetrates into the conjunctiva and from there it will move into the inner ocular tissues, either 
through the corneal or through the scleral route (147-150).
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 It is also likely that this route of administration will maintain a steady drug concentration 
in the tear film (148). To the best of our knowledge, there have been few literature reports that 
studied trans-eyelid drug delivery (147-150). The data demonstrated prolonged drug levels on the 
ocular surface following application of a semisolid dosage form applied on the eyelid compared 
to the conventional formulation instilled in the eye (147,150).  
 Protransfersome gels were extensively explored for superior transdermal drug 
delivery (152). These formulations rapidly convert into transfersomes, ultradeformable and 
ultraflexible vesicles, by absorbing water from the skin, and efficiently penetrates into the deeper 
skin layers (43,152-155). Unlike the proliposome and proniosome systems, these gels have an edge 
activator alongside the vesicle forming components, which provides the flexibility to the 
transfersomes and, thus, enhances the transcellular permeation across the intact skin (43,156-159). 
Various mechanisms have been proposed to explain the ability of vesicles to modify drug diffusion 
through the skin (156-160). Principally, fluidization of the regular skin structure, because of the 
inclusion of the vesicle into the intercellular lipid layers of the skin, is important in overcoming 
the barrier property of the stratum corneum (157-161). The higher concentration gradient, between 
the skin and drug loaded vesicles, is another driving force that improves drug permeation through 
the skin (152,157-161). 
  The effectiveness of a protransfersome gel formulation for eyelid drug delivery, 
loaded with TA, has not been investigated till date. Thus, the goal of the current research was to 
develop and investigate the TA loaded protransfersome gel (PTF) as effective eyelid drug delivery 
system for improved ocular pharmacotherapy.  
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5.2. Materials and Methods 
Phospholipon 90H (PL) was procured from Lipoid, LLC (Newark, NJ, USA), Kolliphor 
TPGS (D-alpha tocopheryl polyethylene glycol 1000 succinate) was obtained from BASF 
Corporation (NJ, USA), (Sorbitan monostearate (Span 60 (S60)) was received from Sigma Aldrich 
(St. Louis, MO, USA. Cholesterol (CH) was procured from Alfa Aesar (Ward Hill, MA, USA). 
TA, Amicon® Ultracentrifugal filter devices with regenerated cellulose membrane (molecular 
weight cut off 100 kDa), high performance liquid chromatography (HPLC) - grade solvents, and 
other chemicals (analytical grade) were supplied by Fisher Scientific (Hampton, NH, USA).  
5.2.1. Preparation of TA loaded Protransfersome gels 
PTF were manufactured as per previously reported technique (152,158). Briefly, the 
quantities of TA, the vesicle forming components (PL, CH and S60) and, the edge activator 
(TPGS) were accurately weighed in a clean glass vial and then, appropriate volume of 
Table 5.1: Composition of TA protransfersome gels and their physicochemical evaluation parameters 
(mean± SD; n=3). 
Component/Evaluation 
parameter 
PTF 1 PTF 2 PTF 3 
TA (mg) 10 10 10 
PL (mg) 200 200 200 
CH (mg) 34 34 34 
S60 (mg) 30 30 30 
TPGS (mg) 30 30 30 
Ethanol (mg) 100 200 400 
Water (mg) 500 500 500 
Assay (%) 92.1 ± 3.2 94.5 ± 2.6 95.7 ± 2.2 
Content Uniformity (%) 80.2 ± 11.5 89.5 ± 3.1 92.4 ± 2.7 
Particle size (nm) 366.4 ± 6.6 184.5 ± 6.8 235.5 ± 4.6 
PDI 0.52 ± 0.13 0.30 ± 0.08 0.30 ± 0.05 
ZP - 21.7 ± 1.7 -21.4 ± 2.3 - 25.3 ± 3.6 
%EE 64.3 ± 4.4 89.4 ± 2.2 76.4 ± 2.1 
- TA, PL, CH, S60 and TPGS indicates, triamcinolone acetonide, phospholipon 90H, cholesterol, 
span 60, and TPGS, respectively. 
- ZP and %EE represents zeta potential and % entrapment efficiency, respectively. 
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alcohol was incorporated. Later, the glass vial was closed with the screw cap and placed in 
a water bath maintained at 60-700 C. 
The contents in the glass vial was melted to form a homogenous viscous fluid, to which, 
appropriate quantity of water (maintained at same temperature) was added in a dropwise manner 
with constant mixing till the translucent gel was formed. Further, the PTF was allowed to attain 
room temperature and utilized for further studies. The composition of PTF formulations is given 
in Table 5.1. 
5.2.2. Quantification of TA in in vitro samples 
TA content in all the in vitro samples were analyzed using high performance liquid 
chromatography (HPLC) method reported earlier (162). The HPLC system comprising of Waters 
717 plus auto sampler, Waters 2487 dual absorbance detector, 600 Waters controller pump, and 
an Agilent 3395 Integrator. A mobile phase of a 1:1 isocratic solution of water and acetonitrile was 
passed through a Luna® C18 (4.6 mm × 250 mm) column at a flow rate of 1 mL/min; 25µL of 
sample was injected into the mobile phase and, the column eluents were detected for TA at 
wavelength (λmax) of 254 nm. 
5.2.3. Assay, Content Uniformity and Entrapment Efficiency  
To determine the assay and content uniformity in the PTF, known amount of formulation 
was dissolved in methanol and centrifuged (AccuSpin 17R centrifuge, Fisher Scientiﬁc, USA) at 
13,000 rpm for 15 min. The supernatant was separated, and TA content was quantified using 
HPLC.  
Entrapment efficiency (EE (%)) was determined by dispersing known amount of PTF 
(equivalent 1 mg TA) in 1 mL water and then vortexed to form a homogenous dispersion. Further, 
a 500 uL aliquot of this dispersion was added to the sampler holder in 100-kDa centrifugal filter 
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unit (Amicon Ultra) and centrifuged at13,000 rpm for 15 min. The drug in the filtrate was estimated 
by HPLC method and the %EE was calculated by using the equation 1:  
0 0D EE  E
F7 − F8
F7 H X
				//											1 
Where, wi is the total drug content and wf is the free drug present in the aqueous phase. 
5.2.4. Morphometric characterization  
The hydrodynamic radius, zeta potential (ZP) and polydispersity index (PDI) of the 
transfersomes formed from the PTF formulations were determined by photon correlation 
spectroscopy using a Zetasizer Nano ZS Zen3600 (Malvern Instruments, MA, USA) at 25°C in 
clear, disposable folded capillary cells. Known amount of PTF formulation was dispersed in 1 mL 
of water and vortexed to get a homogenous dispersion. This transfersome dispersion was diluted 
10,000 times with bi-distilled water, and the particle size and PDI measurements were obtained 
using a helium-neon laser of 633 nm. Zeta potential (ZP) measurements were also carried out at 
25°C using the laser Doppler velocimetry function of the same instrument. 
5.2.5. Polarized Microscopy  
The crystalline nature of pure TA and the protransfersome gels was observed under optical 
polarized microscopy, as reported earlier (163,164). Briefly, the test samples were placed on the 
rectangular cover slips and then loaded onto the optical microscope with uncrossed polarizer 
(Nikon Eclipse E600 Pol, Nikon Instech Co., Japan). The images with optical birefringence of 
drug was recorded.   
5.2.6. Optical microscopy to observe the formation of transfersomes from PTF 
The formation of transfersomes from PTF was observed under optical microscopy, as 
reported earlier, (Carl Zeiss AxioLab A1, CA) and the images were captured with live capture 
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module software (Zen, CA) (158). The protransfersome gel was hydrated with 5 mL water and 
gently agitated. Then the gel was placed in the well of a concave glass slide, cover slip was placed 
on the slide and placed under microscope. Microphotographs of transfersomes formation were 
captured at 45X magnification.  
5.2.7. In vitro trans-eyelid permeability studies 
In vitro trans-eyelid flux was measured using isolated rabbit eyelids as per the methods 
established for assessing flux across the skin (147,152). In brief, the rabbit eyelids will be washed 
with IPBS (pH 7.4) after removing the hair on the eyelid with epilator and mounted, as an inverted 
cup, on the Valia-Chien diffusion cells, such that the conjunctival side of the eyelid face towards 
receiver chamber. The donor chamber was then tightly secured so that the eyelid surface will be 
exposed to the donor compartment. Accurately weighed optimized PTF or marketed formulation 
(Triamcinolone Acetonide cream USP, 0.5 % w/w), equivalent to 1 mg of TA, was applied on the 
eyelid surface in the donor chamber. At predetermined time points, 600 µL aliquots was collected 
from the receiver cell and replaced with equal volume of fresh medium. The samples were 
quantified for the drug content using HPLC-UV method. 
Cumulative amount of drug permeated (Mn), steady state flux (J) and trans-eyelid 
permeability (Papp), across the rabbit cornea, were estimated in order to study the transport of TA 
across rabbit eyelid (147,148). The cumulative amount of TA was calculated as per the equation: 
                                    JK 	BLMLK 	∑ BNOPMLOPOKOP        (2) 
Where, n is sampling time point; Vr and VS are the volume in the receiver chamber (mL) 
and the volume of the sample collected at the nth time point (mL), respectively and Cr(n) is the 
concentration of the drug in the receiver chamber medium at nth time point (µg/mL).                    
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The rate of TA transported across rabbit eyelid was calculated using the slope of the 
cumulative amount of TA transported versus time plot. The steady state flux of TA was determined 
using the following equation: 
                                                     QRSOT  UJ/UV/1                      (3)                        
Where, M is the cumulative amount of drug transported and A is the surface area of the 
eyelid (0.636 cm2).  
The transcorneal permeability of TA was calculated by the following equation:  
                                      WXLYXZ[\R\V]	WZ^^  _VXZU]	NVZVX	`RSO0aKaL	baKbXKVLZV\aK     (4) 
5.2.8. Ocular Distribution Studies  
Ocular penetration and distribution of TA from optimized PTF and marketed cream 
formulations was evaluated on recently sacrificed New Zealand male albino rabbits (within 30 min 
after euthanization with excess of pentobarbital). The hair on the right upper eye lid in rabbits were 
removed with the aid of epilator and accurately weighed amount of optimized PTF formulation 
and marketed TA 0.5 % w/v cream formulation, equivalent to 1 mg of TA, was applied. At the end 
of 1h and 2h post application, the eyes were enucleated, cleaned with ice cold IPBS (pH 7.4) and 
the ocular tissues were collected. These ocular tissue samples were stored at -80˚C until further 
analysis.  
5.2.9. Sample preparation 
Protein precipitation technique was adopted to extract TA from the ocular tissues. Briefly, 
the isolated ocular tissues:  conjunctiva, cornea, iris ciliary (IC), retina choroid (RC) and the sclera 
were transferred to separate eppendorf tubes. The tissues were dissected into small pieces and 100 
µL of 1 µg/mL prednisolone (PR) was added as the internal standard (IS) to each of the tissue 
samples. After a while, 1mL ice cold methanol with 0.1% formic acid was added to precipitate the 
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proteins. Two hundred microliters of aqueous humor (AH) and 500 µL vitreous humor (VH) tissue 
proteins were precipitated using 200 µL and 500 µL respectively, of ice-cold methanol. All 
samples were vortexed for about 30 sec and sonicated for 5 min, to extract the drug into the solvent. 
Then the samples were centrifuged for 15-30 min at 13,000 rpm, the supernatant was collected and 
analyzed for TA content using the UPLC-triple quadrupole (TQ)-MS system. 
5.2.10. Bioanalytical method 
TA concentration in all the ocular tissues was quantified using Ultra Performance Liquid 
Chromatography system coupled with a triple quadrupole mass spectrometer (UPLC-TQ-MS) 
(Waters, USA). The peaks of both the drug and the IS (PR)) were quantified with respect to the 
specific mass to charge (m/z) values (m/z 435 and 361 for TA and PR, respectively). Two 
microliters of the sample were eluted through BEH C18 (100mm×2.1 m, 1.7 µm) Acquity UPLC® 
column and separated using an isocratic mobile phase consisting of acetonitrile with 0.1% formic 
acid and water with 0.1% formic acid in the ratio of 98:2 respectively. The method showed a limit 
of detection (LOD) and quantification (LOQ) of 0.1 ng/mL for TA and IS respectively. All the 
instrument functions were operated and managed by Mass Lynx software (version 4.1, Waters, 
Milford, MA, USA).  
5.2.11. Statistical analysis 
A one-way analysis of variance (ANOVA) along with Tukey’s post hoc test (version 5.00; 
GraphPad Prism Software, San Diego, CA, USA) was used to analyze the data obtained from the 
ocular distribution studies, and the statistically significant difference between the set of 
formulations was observed at a ‘p’ value less than 0.05 (p<0.05). 
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5.3. Results and Discussion  
5.3.1 Physicochemical properties of PTF  
PTF formulations were successfully developed changing the ethanol composition, keeping 
all other components at same proportions. The physicochemical evaluation parameters are 
enumerated in Table 5.1. The drug loading in all the PTF formulations (~ 1% w/w) were ~ 2 folds 
higher, compared to the topical triamcinolone USP marketed cream dosage form (0.5 % w/w), 
with ~92- 96 % assay (Table 5.1). The content uniformity of the PTF 1 formulation was 80.2 ± 
11.5, which was lower than that seen in PTF 2 and PTF 3 formulations. This suggests poor 
distribution of TA in the lipid matrix at this proportion of ethanol. The particle size of the PTF 
formulations (184.5 – 336.4 nm) decreased to some extent as the ethanol composition increased 
but, it increased again upon further increase in the ethanol proportion (Table 5.1). In contrast, the 
% EE in the PTF formulations increased upon increase in the amount of ethanol to an extent but it 
decreased again upon further increase in the ethanol amount in the formulation (Table 5.1). It has 
been reported that in the vesicular systems, ethanol helps in i) lowering the transition temperature 
of the lipids, and thereby, allows the lipophilic drug partitioning into the phospholipid bilayers; ii) 
attaining the gel phase due to regular arrangement of bilayer components, unlike liquid crystalline 
phase where irregular arrangement of PL and CH is seen; and, iii)  permeability of the bilayer 
membrane (158, 165-167). Thus, at lower ethanol proportion the TA partitioning into lipid 
components was less which resulted in larger transfersomes with less drug entrapment. While at 
higher concentration of ethanol, the %EE dropped due to increased permeability of the bilayer 
membrane. Hence, PTF 2 formulation, which formed 184.5 nm size transfersomes with ~90% EE, 
was optimized and taken for further studies (Table 5.1).  
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5.3.2 Polarized Microscopy 
Polarized microscopic images of pure TA and PTF 2 formulations are presented in Figure 
5.1. The optical birefringence of pure TA showed interference colors (Fig 5.1A). The polarized 
optical microscopic images of PTF 2 formulation revealed the absence of crystalline drug in the 
gel formulation, confirming the solubility of drug in lipid phase (Fig. 5.1B). 
5.3.3 Formation of Transfersomes from PTF 
Figure 5.1: Optical polarized microscopic images of (A) pure TA B) PTF 2. 
Figure 5.2: Photomicrographs showing the formation of transfersomes under optical microscope: (A) gel 
surface immediately after hydration, B) Tubular structure formation, C) Transformation of tubular projection 
to vesicular form and D) Multilamellar transfersomes.  
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 The formation of transfersomes from PTG formulation are illustrated in Figure 5.2. The 
optical microscopic studies demonstrated projection of globular structures on the surface of gel 
matrix (Fig. 5.2A), initially upon hydration of PTF 2, and they transformed into tubular structure 
(Fig. 5.2B and Fig. 5.2C) and finally, formed as multilamellar transfersomes (Fig. 5.2D). These 
findings were consistent with the earlier reports which demonstrated the formation of liposomes 
from proliposomes gel formulation (158). 
5.3.4 In vitro trans-eyelid permeability study 
Trans-eyelid permeability parameters of TA from marketed and PTF 2 formulations are given in 
Table 5.2. The results from in vitro trans-eyelid permeation studies suggested a ~2-fold 
improvement in TA flux and permeability across the eyelid with the PTF 2 (p<0.05) formulation 
compared to marketed dosage form (Table 5.2). This demonstrates efficient partitioning of the 
lipid vesicles into the intercellular lipid layers in the eyelid - thus, increasing the permeation (150, 
152-1754). Reports in the literature demonstrated immediate formation of vesicles from the pro-
vesicular gel formulation and increased vesicle-skin interaction (152-154). The phospholipid in 
the vesicle structure allows immediate partitioning of this flexible vesicle, transfersomes, into the 
lipid layers of the eyelid through the intercellular passages (17-19). Moreover, the destabilization 
Table 5.2: In vitro trans-eyelid permeability parameters of TA from optimized PTF and marketed 
formulations (mean± SD; n=3) 
Formulation Flux (µg/h/cm2) Papp x 10 5 (cm2/h) 
Triamcinolone acetonide 
USP, 0.5% w/w 
0.31 ± 0.16  6.3 ± 3.2 
PTF 2 0.69 ± 0.28* 13.8 ± 5.6* 
- PTF 2 and Papp indicates the optimized protransfersome gel formulation and apparent permeability, 
respectively. 
- *- represents the level of significance at p<0.05 between PTF 2 and triamcinolone acetonide marketed 
formulation. 
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of skin layers by Span 60 and TPGS results in improved permeation of TA across the eyelid (155, 
157-159,161). 
5.3.5 Ocular Distribution Studies  
TA levels in different ocular tissues of the rabbits (carcass) treated with PTF 2 and 
marketed formulation was delineated in Table 5.3. ~2-13 fold higher TA levels were seen in the 
conjunctiva, cornea and sclera of the rabbits receiving the PTF 2, in contrast to the marketed 
formulation (p<0.05) (Table 5.3). The TA levels seen in these ocular tissues of the rabbits treated, 
with PTF 2, were upto 2-fold higher at the 2h time point, compared to 1h (Table 5.3).  
This suggests continuous absorption of TA from PTF, through the eyelid, into conjunctiva 
and other exterior ocular tissues, which will thus allow a sustained ocular delivery platform. 
Furthermore, at any given time point, the TA levels in the rabbits receiving the protransferosome 
gel formulation was significantly better than those treated with marketed formulations (p<0.05) 
(Table 5.3). The results demonstrated greater permeability characteristics, of protransfersome gel 
Table 5.3: The levels of triamcinolone acetonide from PTF 2 and marketed formulation in the rabbit ocular 
tissues, at 1h and 2h post eyelid application (mean ± SEM; n=3). 
Formulations PTF 2 Marketed 
Time (h) 1 2 1 2 
O
cu
la
r 
ti
ss
u
es
 
Conjunctiva (µg/g) 4.78 ± 1.04 * 8.5 ± 2.79 * 2.3 ± 1.19 2.38 ± 0.5 
Cornea(µg/g) 4.24 ± 0.96 * 13.04 ± 0.56 * 0.32 ± 0.32 1.76 ± 0.96 
IC (µg/g) 0.68 ± 0.079* 0.88 ± 0.061* 0.20 ± 0.056 0.47 ± 0.019 
AH (ng/mL) 54.03 ± 7.43 * 125.32 ± 27.91 * 21.19 ± 12.37 40.54 ± 1.19 
Sclera (µg/g) 11.07 ± 5 * 11.45 ± 1.8 * 0.45 ± 0.15 1.2 ± 0.25 
RC (µg/g) 1.07 ± 0.003* 1.79 ± 0.4 * 0.21 ± 0.14 0.52 ± 0.06 
VH (ng/mL) 6.25 ± 1.37 * 43.66 ± 17.84 * 1.20 ± 0.40 4.5 ± 0.71 
IC-Iris-ciliary body; AH-aqueous humor; VH-vitreous humor; RC-retina-choroid 
*-indicates significantly different with respect to the marketed formulation, at respective time point (p<0.01) 
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system, through the eyelid, thus presented drug to the deeper ocular tissues (147,150,152). The 
only in vivo trans-eyelid delivery investigation reported dexamethasone levels in the anterior 
segment ocular tissues following the application of a poloxamer gel formulation on the eyelid of 
conscious rabbits (150). The permeability of TA and dexamethasone through ocular tissues has 
been reported to be largely similar due to the similar physicochemical behavior (168,169). In view 
of this, the levels of TA seen in the conjunctiva, cornea and AH with the protransfersome gel 
formulation were comparable with those obtained with dexamethasone from the poloxamer based 
gel formulation at the 2h time point. TA levels were also noticed in back-of-the eye tissues, the 
vitreous humor and retina-choroid.  Furthermore, the levels of TA in ocular tissues, especially in 
AH and VH were significantly higher than the minimum therapeutic concentrations of TA - 1.7 
and 6.5 ng/mL, respectively (170-172).  
5.4. Conclusion 
TA protransfersome gel formulations were successfully prepared with at least a two-fold 
higher drug load, compared to the marketed topical dosage form, which allows higher, localized, 
concentration gradients. Microscopic studies confirmed complete drug dissolution in the lipid 
phase and rapid formation of transfersomes on hydration. Significantly higher trans-eyelid TA 
permeation with the protransfersome gel formulation – demonstrated their potential in enhancing 
drug delivery to the ocular surface and deeper tissues via the eyelid. Experiments in rabbit 
carcasses confirmed that TA efficiently penetrated into the eyelid and formed a depot leading to 
improved concentration-time profiles in all ocular tissues tested. The overall results suggest that 
trans-eyelid protransferosome gel formulations can provide a platform for the sustained delivery 
of therapeutic agents to both the surface of the eye as well as the anterior and posterior segment 
ocular tissues.  
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